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ABSTRACT 
Mehmet Murat Koseoglu 
CELL CYCLE REGULATION OF THE STEM LOOP BINDING PROTEIN: 
A KEY REGULATOR IN HISTONE mRNA METABOLISM 
(Under the direction of Prof. Dr. William F. Marzluff) 
 
Metazoan replication-dependent histone mRNAs are unique among eukaryotic 
mRNAs since they lack polyadenylated tails, instead ending in a conserved stem-loop.  
Expression of these histone mRNAs is tightly cell cycle regulated mostly via 
posttranscriptional mechanisms which are mediated by the 3’ stem-loop. The stem loop 
binding protein (SLBP), which binds to 3’ end of histone mRNAs, plays a major role in 
histone mRNA metabolism by participating in multiple steps including histone mRNA 
processing, translation and stability.  SLBP expression is limited to S phase, and cell-cycle 
regulation of SLBP is one of the major mechanisms that restrict histone mRNA biosynthesis 
and thus histone production to the S phase.  
The SLBP level is quite low during G1 and it dramatically increases towards S phase. 
It has been shown that the low level of SLBP at early G1 is due to the low translation 
efficiency of SLBP mRNA and the translation of SLBP is activated as cells approach S 
phase. At the end of S phase, SLBP is rapidly degraded depending on phosphorylations of 
two threonines in N-terminal SFTTP sequences.   
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In this dissertation, I have further elucidated the molecular details of the mechanisms 
involved in cell cycle regulation of SLBP expression.  I have determined Cyclin A/Cdk1 as 
the kinase that triggers degradation of SLBP at the end of S phase by phosphorylating SLBP 
Thr61. Cyclin A/Cdk1 activity is cell cycle regulated similar to SLBP Thr61 phosphorylation 
and is the major activity in late S-phase cells that phosphorylates Thr61.  We propose that as 
Cyclin A/Cdk1 activity reaches to certain level near the end of S-phase, and it triggers SLBP 
degradation as one of the mechanisms to shut down histone mRNA biosynthesis.  
 Moreover, I have shown that the SLBP coding sequence is sufficient to induce low 
translational efficiency of SLBP mRNA as a regulation to keep the SLBP protein level low at 
early G1. I further showed that at some point in early G1, SLBP translation efficiency 
recovers back to S phase level but protein stability decreases.  It is likely that there is then 
regulated degradation of SLBP limiting SLBP level until next G1/S.    
 
 
 
 
 
 
 
 
 
 
 
 iii
  
 
 
TO MY BELOVED WIFE 
  
BEYZA NUR  
 iv
  
  
ACKNOWLEDGEMENTS 
I would like to express my most sincere gratitude to my mentor Dr. William Marzluff 
for his guidance, support and patience. He had trust and confidence to allow me to pursue my 
own ideas and mature my own way as a scientist.  It was a true privilege and chance to be his 
student. 
I would like to express special thanks to Dr. Lee M Graves with whom we collaborate 
in kinase project. I owe him special thanks not only for his scientific guidance but also his 
great kindness.  
My special thanks to the members of the Marzluff and Graves Lab, for their help and 
all the scientific discussions.  
I would especially like to thank the members of my thesis committee, Dr Jeff Dangl, 
Dr. Robert J. Duronio and Dr Yue Xiong, for all of their helpful advice and discussions. I 
appreciate deeply their time, patience and counsel for this work and my next steps in 
scientific career. 
I would like to thank the people of North Carolina and Department of Biology at 
UNC Chapel Hill for the opportunity to study at and be part of this great school. 
I would like to thank my family. I feel indebted to my parents, Turkan and Ahmet 
Koseoglu, my sisters Gulsen Koseoglu, Birsen Uysan, and my brothers Zeki and Yusuf 
Koseoglu and my brother in law Ahmet Uysan for their continuous support and love. 
 v
              Next, I would like to thank deeply to Sumeyye and Nevzat Kazgan for their support 
and friendship to me and my family during my graduate work. I owe special thanks to 
Nevzat, Canguzel and Fahir Zulfikar, and Aziz Sancar especially for their support during my 
most difficult times in graduate school after I lost my mother. 
             Finally, I am grateful to my wife, Beyza Nur Koseoglu, for her tolerance, support 
and extraordinary patience. I am thankful to Beyza for putting up with the life of a graduate 
student and having provided all the love, encouragement and support. And special thanks to 
my daughter Zeynep Turkan Koseoglu for the great joy she brought to my life that made 
everything easier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
  
 
TABLE OF CONTENTS 
LIST OF TABLES……………………………………………………………………. …ix 
LIST OF FIGURES……………………………………………………………………….x 
 
CHAPTER I 
INTRODUCTION………………………………………………………………………...1 
                        CELL CYCLE AND ITS CONTROL……………………………….......1 
                      Regulation of the Cyclin/Cdks……………………….……………..4 
                      Cyclin/Cdks and substrate recognition…………………………......7 
                      Ubiquitin mediated degradation and cell cycle…………………….8 
 
                      Translation control and cell cycle……………………….………...11 
                       
                        S PHASE: REPLICATION OF CHROMOSOMES…………….….....15   
 
                                  Replication- dependent histone genes and cell cycle..…….…....…15 
 
                                 Cell Cycle regulation of SLBP-The key player in histone 
                                 mRNA metabolism…………………………………………….……18 
 
  
    
CHAPTER II 
CYCLIN A/CDK1 TRIGGERS DEGRADATION OF SLBP AT  
THE END OF S PHASE BY PHOSPHORYLATING Thr61………………..20 
 
INTRODUCTION…..…………………………………………………..20 
RESULTS……………..………………………………………………....22 
 vii
DISCUSSION………………..……………………………….…………..29 
FIGURES AND TABLES………………………………...……………..35 
MATERIALS AND METHODS…………………………………….….65 
 
 
CHAPTER III 
G1 PHASE REGULATION OF SLBP EXPRESSION……………………….68 
 
INTRODUCTION…………………………………………………….…68 
RESULTS……………..……………………………………………….....69 
DISCUSSION………………..……………...………………….………..74 
FIGURES…………………………………………………..……….……78 
MATERIALS AND METHODS………………………………….……95 
 
CHAPTER IV 
             CONCLUDING DISCUSSION………….…………………….……………….97 
REFERENCES…………………………………………………………………….……103 
 
 
 
 
 
 viii
LIST OF TABLES 
 
Table 1            List of kinase inhibitors analyzed for their effect on SLBP S/G2 
                         degradation……………………………………………………………...39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix
LIST OF FIGURES 
 CHAPTER II 
Figure 1 SLBP expression during the cell cycle……………....…………..............35 
Figure 2 S/G2 degradation of SLBP is Roscovitine sensitive…………….............37 
Figure 3 SLBP Fragment (aa.55-121) that is designed 
                        as substrate for kinase assays…..……………….………………....…….41 
 
Figure 4          SLBP Fragment with only two phosphor-acceptor sites  
                        (Thr61/62) is sufficient to introduce cell cycle 
                        dependent degradation, in vivo…………..………………….............…..43 
 
Figure 5          SLBP Fragment is phosphorylated on Thr61  
                         by a Cyclin/Cdk………………………………………………………….45 
 
Figure 6          Peak KRKL-dependent and roscovitine-sensitive 
                        phosphorylation was detected with late S phase lysate………...……...47 
 
Figure 7          Phosphorylation detected at late S phase  
                         is on Thr61…………………………………………………………........49 
 
Figure 8          Cdk1 is the major Thr61 kinase in late S phase lysate……........….….51 
 
Figure 9          cyclin A/Cdk but not cyclin B/Cdk requires KRKL region for 
phosphorylating Thr61…………………………………………….…....53 
                        
Figure 10        Cdk1 knock down inhibits late S phase SLBP 
degradation……………………………………………………………....55 
 
Figure 11        Thr61 to Glu change mimic phosphorylation of Thr61 for  
                        Degradation Purposes……………………………………………….….57 
 
Figure 12        Model for triggering SLBP degradation  
                        at S/G2……………………………………………………………...…....59 
 
Figure 13        CkII inhibitors inhibit SLBP degradation at S/G2…………….……..61 
 
Figure 14        Thr 60 to Glu change did not rescue CKII inhibitor 
effect………………………………………………………………….….63 
 
 
CHAPTER III 
 x
Figure 1 SLBP level stays low until the next S Phase in HeLa cells……..…..…..78 
Figure 2 SLBP translation efficiency is low in early G1 cells …………………...80 
Figure 3 SLBP mRNA shifts from small to large polysomes between  
                        early G1 and S phase.………..……………….………. ……………..…..82 
 
Figure 4           SLBP Coding Sequence Clone (his-SLBP) expression is low  
                         at G1……………………………………………………………………....84                        
 
Figure 5 SLBP coding sequence is sufficient to introduce 
                        low translation efficiency in early G1 cells………..…...………………..86 
 
Figure 6 SLBP translation efficiency recovers to S phase level between 
early and mid-G1………………………………………..………………..88 
 
Figure 7 SLBP is less stable at mid-G1…………………………………….……...90 
Figure 8 Model for regulation of SLBP expression in G1………………….…….93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi
CHAPTER I 
INTRODUCTION 
 
CELL CYCLE and ITS CONTROL 
 
Progression through the eukaryotic cell cycle is highly controlled series of events that 
lead to eukaryotic cell reproduction. In each cycle, cells must coordinate DNA synthesis and 
chromosomal segregation to generate an exact replica of themselves. These events are 
confined to discrete periods called synthesis (S phase) when DNA is replicated once and 
mitosis (M phase) when resulting duplicated chromosomes are equally segregated into two 
daughter cells. In most of the cycles, these periods are separated by two gap phases called G1 
and G2. The first gap phase, G1, occurs between M and S phase and the second gap phase, 
G2 occurs between the end of S-phase and M phase. 
Eukaryotic cell cycle progression is a tightly regulated process that depends on the 
orderly activation and inactivation of a series of Ser/Thr kinases called Cyclin-dependent 
kinases (Cdks) (Hunter and Pines, 1991; Hunter and Pines, 1994; Norbury and Nurse, 1992). 
Cdks are active only after association with certain Cyclins (Morgan, 1995), whose synthesis 
and degradation are tightly controlled during cell cycle (King et al., 1996; Hershko, 1996; 
Elledge and Harper, 1998).  Different Cyclin/Cdks have been shown to be involved in 
regulation of different phases of the cell cycle: Cyclin D/Cdk4/6 controls G1 progression, 
Cyclin E/Cdk2 mediates S phase entry, CyclinA/Cdk2 is important for S phase progression, 
and Cyclin A/B/Cdk1 controls G2/M transition during which active CyclinB/Cdk1 is the 
actual Mitosis Promoting Factor (MPF) (Sanchez and Dynlacht, 2005). 
In addition to binding the Cyclin subunit, Cdk activity is regulated by 
posttranslational modifications such as phosphorylation/dephosphorylation, and association 
with group of inhibitory proteins collectively called CKIs (Morgan, 1995; Sherr and Roberts, 
1995; Sherr and Roberts, 1999; Xiong, 1996). One class of CKIs, comprised of p21, p27, and 
p57, binds and inhibits Cyclin/Cdk complexes, whereas the other class of Cdk inhibitors, 
Ink4, p15, p16 and p18, binds to Cdk4/Cdk6 and prevent their activation by the G1 Cyclin, 
Cyclin D. 
The eukaryotic cell cycle is characterized by a series of transitions from one phase to 
another. Different Cyclin/Cdk complexes are activated at a certain time window and regulate 
several critical downstream effectors by specific phosphorylation. This sequential activation 
results in accomplishment of various biochemical events characteristic of each cell-cycle 
stage and triggers entry into the next cell cycle phase. The places where cells monitor the 
completion of previous phase and then start the initiation of next phase are called 
checkpoints. The first checkpoint is called Start or Restriction point. This is particularly 
important because at this point cells evaluate external signals such as growth conditions and 
inhibitory or activating signals and decide to continue dividing or to exit from the cell cycle 
into a quiescent state which is called G0. 
In resting cells (G0), activation of Cyclin D transcription in response to mitogens is 
considered as the first step to drive a cell towards division.  Cyclin D protein then associates 
with Cdk4/6 and initiates G1 progression (Weinberg, 1995). Cyclin D is very a unstable 
protein and this in part maintains the requirement for continued synthesis of Cyclin D, and 
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hence the presence of mitogens at this point.  The main targets of Cyclin D/Cdk4/6 are 
members of the retinoblastoma tumor suppressor protein (RB) family, which occupy a 
central role in G1 progression. In the hypophosphorylated form, Rb interacts and represses 
the E2f transcription factor family (Weinberg, 1995). E2fs in association with Dp proteins 
(Dp1 and Dp2 in mammals) regulate the expression of various critical genes for G1/S 
progression. In the phosphorylated form, Rb dissociates from the E2f/Dp complex which 
then can activate numerous genes required for G1/S progression and S phase including 
Cyclin E and Cyclin A which are called G1/S and S phase cyclins respectively (Duronio et 
al., 1995; Sherr and Roberts, 1999). Cyclin E/Cdk2 (also Cyclin A/Cdk2) can further 
phosphorylate Rb keeping it inactive, and producing a positive feed back loop which allows 
to cell to reach the point where cell cycle progression become independent of mitogen 
presence and the cell passes through the so called Restriction point. 
When G1/S and S phase specific Cyclin/Cdks, Cyclin E/Cdk2 and Cyclin A/Cdk2 are 
activated, they phosphorylate downstream substrates not only required for triggering next cell 
cycle events but also remove negative impediments to G1 progression. For example, Cyclin 
E/Cdk2 phosphorylates p27, a Cyclin/Cdk2 inhibitor that prevents G1/S progression and 
triggers p27 degradation (Vlach et al., 1997).  They also phosphorylate factors involved in 
DNA replication, including Mcm 2-7, Cdc7, Cdc6, Cdt1 allowing the cells both enter and 
then complete S-phase.  At the end of S-phase cells enter G2, defined as a period without 
DNA replication prior to nuclear envelope breakdown, chromosome condensation and entry 
into mitosis.  Exit from G2 into M-phase requires passage through the G2/M checkpoint, 
which then results in activation of M phase Cyclin/Cdk complexes which are Cyclin A/Cdk1 
and Cyclin B/Cdk1.  These M phase Cyclin/Cdks drives the cell to the next checkpoint called 
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the metaphase to anaphase checkpoint where cells make sure of proper spindle assembly and 
chromosome alignment. At metaphase-anaphase transition, the anaphase promoting complex 
(APC) is activated, result in degradation of the Cyclin A and B as well as other proteins 
involved in chromosome cohesion.  This then results in the separation of sister chromatids, 
exit from mitosis and cytokinesis. 
 
Regulation of the Cyclin/Cdks: 
 
In yeast (S.pombe and S.cerevisiae) all cell cycle events are controlled by a single 
Cdk called Cdk1 which is also called Cdc2 (S.pombe) and Cdc28 (S.cerevisiae). The activity 
and substrate specificity of this kinase is controlled by different cyclins at different cell cycle 
stages. In multicellular eukaryotes, there are multiple Cdks as well as multiple Cyclins. In 
mammals, there are four Cdk1 like proteins that have a direct role in regulation of the cell 
cycle. In mammalian cells, two of these cdks, Cdk1 and Cdk2 control cell cycle transitions, 
and operate primarily at M and S phase, respectively. In addition to these, two other Cdks 
called Cdk4 and Cdk6 are involved in control of cell cycle entry in response to extracellular 
signals.  Also another family member, Cdk7, is involved in cell cycle regulation indirectly by 
acting as Cdk Activating kinase that phophorylates other Cdks. 
Activation of all Cdks requires binding of Cyclins and in most cases full activation 
also requires a phosphorylation of a threonine residue near the kinase active site. During the 
cell cycle, periodic synthesis and rapid targeted degradation of different cyclins is a major 
mechanism that irreversibly drives cell cycle progression by changing the activity of different 
Cyclin/Cdk complexes. 
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Most of the information about the structure of the Cdks has been obtained from the 
crystal structures of Cdk2, Cyclin E/Cdk2 and Cyclin A/Cdk2 (De Bondt et al., 1993; Jeffrey 
et al., 1995; Honda et al., 2005). Cdks, which have a two-lobed structure like other kinases, 
are inactive in the absence of Cyclins due to two structural modifications. The active site of 
the Cdks is present in a buried cleft between these two lobes. ATP binds deep in the cleft 
with its phosphates oriented outwards. The substrate protein normally interacts with the 
entrance of this active-site cleft. But in the absence of Cyclins, this region is blocked by large 
flexible loop called T- loop or activation loop. Also, key residues in the ATP binding site are 
not ideally oriented which further suppresses the Cdk activity. Thus, Cdks require significant 
changes in the structure of their active site to become active. 
Cyclin binding introduces significant conformational changes in the Cdk active site. 
The major change occurs within the T- loop, in which L12 helix changes to a beta strand, 
which no longer blocks the substrate binding site and makes the active site available. Also 
major changes occur at the ATP binding site resulting in the proper positioning of the ATP 
phosphates for an efficient phosphotransferase reaction.  As mentioned above, full activation 
of a Cdk requires phosphorylation of a threonine residue near to the kinase active site 
(Thr161 in Cdk1, Thr162 in Cdk2).  In mammalian cells, this phosphorylation can occur after 
Cyclin binding and causes the T-loop to flatten and interact more extensively with the 
binding Cyclin partner. Further, this phosphorylation enhances the interaction with the 
substrate with SPXK/R, the canonical Cdk target sequence (Russo et al., 1996). The 
activating Thr 160 phosphorylation is catalyzed by enzymes called Cdk activating kinases 
(CAKs) (Harper and Elledge, 1998).  These enzymes are constantly active during the cell 
cycle and are not regulated by any known cell cycle pathway. Therefore, Cyclin binding but 
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not the activating phosphorylation is considered the highly regulated and rate-limiting step in 
Cdk activation, in vivo. 
Although the activating phosphorylation is not regulated, two inhibitory 
phosphorylations on Tyr 15 and Thr 14 have a significant role in regulating Cdk activity. 
These residues are present at the roof of the kinase ATP-binding site and their 
phosphorylations introduce inhibition by interfering with the orientation of ATP phosphates. 
The phosphorylation state of these two inhibitory phosphorylations is regulated by opposing 
effects of kinase and phosphatases. Wee1/Mik1 is the kinase that introduces the Tyr 15 
inhibitory phosphorylation. Also in vertebrates another kinase called Myt1 can phosphorylate 
both Tyr 15 and Thr 14. Dephosphorylation of these inhibitory sites is mediated by a family 
of phosphatases called Cdc25 (Morgan, 1997). 
These inhibitory phosphorylations are particularly important in regulation of M phase 
Cdk activation at the onset of mitosis and also have been shown to be involved in G1/S and S 
phase Cdk activation. During late S phase and G2, Cyclin B accumulates and associates with 
Cdk1 but the Cyclin B/Cdk1 complex stays inactive due to these inhibitory phosphorylations. 
At G2/M, there is a large increase in Cdc25C activity and a decrease in Wee1 activity that 
together triggers a rapid increase in Cyclin/Cdk1 activity and cause M phase entry. Also 
removal of inhibitory phosphorylations is important for activation Cyclin/Cdk2 complexes 
for G1/S and S phase progression. 
In vertebrates, Cdc25 has three members, Cdc25A, Cdc25B and Cdc25C, and their 
activity level differs throughout the cell cycle (reviewed in (Boutros et al., 2006). Cdc25A 
expression and activity appears at G1/S and peaks at M phase. It is involved primarily in 
Cyclin/Cdk2 activation to allow S-phase entry and S phase progression, and also may 
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participate in Cyclin/Cdk1 activation at G2/M. Cdc25B expression and activity starts to 
increase at late S phase and peaks at G2 and believed to have a role in G2/M regulation of 
Cyclin/Cdk1. Finally, although Cdc25C expression doesn’t change significantly during cell 
cycle, its activity peaks at G2/M and triggers M phase by activating Cyclin B/Cdk1.  Recent 
studies suggest that Cdc25B,C may also have some role in S phase progression supporting 
the recent model that the activities of these three phosphatases are in coordinated 
collaboration throughout cell cycle (Boutros et al., 2006). 
 
Cyclin/Cdks and substrate recognition: 
 
The optimal target sequence for recognition by Cdk1/2 in vitro has been established 
as S/TPXK/R with absolute requirement proline at +1 position and a less stringent need for 
+3 positive charged residue. Although S/TPXK/R sequence appears to be a consensus Cdk 
target site (Nigg, 1995; Songyang et al., 1994; Srinivasan et al., 1995), it is clear that 
different Cylin/Cdks show differences in substrate specifity towards several physiological 
substrates (Dowdy et al., 1993; Dynlacht et al., 1994; Ewen et al., 1993; Krek et al., 1994; 
Peeper et al., 1993; Xu et al., 1994).  Despite the crucial role of Cyclin/Cdk dependent 
phosphorylations during the cell cycle, there is limited knowledge about how individual 
Cyclin/Cdks target different substrates specifically throughout the cell cycle. 
Cyclin subunits are involved in refining the substrate targeting by the core Cdk 
subunit. For example, in mammals Cyclin A/Cdks but not Cyclin B/Cdks can phosphorylate 
pRb related protein p107.  Recently, the S-phase Cyclins, Cyclin E and Cyclin A have been 
shown to be involved in substrate specificity by specifically binding to different substrates at 
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the so called Cy or RXL motif to bring the bound Cdk to the proximity of the substrate. In 
addition to the Cdk inhibitors p21 and p27 (Adams et al., 1996; Zhu et al., 1995), several cell 
cycle key regulators such as E2f1, p107, p130, pRb, p53, Cdc6 have been shown to use 
certain RXL motifs to recruit Cyclin/Cdks for specific phosphorylation events (Dynlacht et 
al., 1997; Lees et al., 1992; He et al., 2005; Hannon et al., 1993; Luciani et al., 2000; Takeda 
et al., 2001). Although the RXL motif appeared to be crucial for several substrates to be 
recognized by Cyclin E or Cyclin A/Cdks, there is very limited example of RXL dependent 
recognition by Cyclin B/Cdk1 (Liu et al., 1999; Malathi et al., 2005).  
Finally, it is clear that substrate recognition is more complex than just the RXL motif 
for cyclins A and E, but residues other than RXL are important for Cyclin recruitment to the 
substrate. For example, although both Cyclin E and Cyclin A can interact with the peptide 
spanning the RXL region of E2F1, full-length E2F1 can only recruit Cyclin A/Cdk2 but not 
Cyclin E/Cdk2. 
In summary, in metazoans, it appears that in vivo each Cyclin/Cdk heterodimer is 
likely to have its own specific group of substrates, and specificity can be determined by 
Cyclins along with the kinase domain. 
 
Ubiquitin mediated degradation and cell cycle: 
 
Along with specific phosphorylation, a major component of cell cycle regulation is 
selective and time-controlled degradation of the critical players by the ubiquitin pathway. 
Ubiquitination of cellular proteins is performed by three classes of enzymes: an ubiquitin 
activating enzyme (E1), an ubiquitin conjugating enzyme (E2) and ubiquitin-protein ligase 
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complex (E3). Repeated transfer of additional ubiquitin molecules results in a polyubiquitin 
chain on the substrate protein which labels it for degradation by the proteosome. 
The specificity of ubiquitin mediated degradation is determined by E3 ligases that are 
generally defined to mediate two distinct functions: catalyzing the isopeptide bond formation 
and recruiting specific substrates (Hershko and Ciechanover, 1998; Hochstrasser, 1996). 
Based on their characteristic motifs, there are two major groups of E3 ligases: RING domain 
and HECT domain E3s.  RING domain E3s contain either an intrinsic ring finger or an 
associated Ring finger protein subunit essential for ubiquitin ligase activity (Deshaies, 1999; 
Pickart, 2001). Multiple different Ring finger E3 ligases, including SCF and APC, have been 
shown to have important roles in the regulation of the cell cycle. 
The SCF (Skowyra et al., 1997; Bai et al., 1996; Feldman et al., 1997) helps control 
the G1/S transition by inducing degradation of Cdk inhibitors p27 and sic1(Vlach et al., 
1997; Pagano et al., 1995; Verma et al., 1997) and degradation of key players like Cyclin E 
(Moberg et al., 2001; Koepp et al., 2001). SCF is a protein complex, consists of a Cullin 
protein, Cul1, a Ring finger protein, Roc1, a F box protein and a linker protein called Skp1 
(Seol et al., 1999; Skowyra et al., 1997; Skowyra et al., 1999). In this complex, the F box 
protein specifically recognizes the phosphorylated SCF target and brings it to Cul1 by 
binding to a linker protein called Skp1 that can bind both Cul1 and F box protein (51). Roc1 
interacts with E2 and binds to the other end of Cul1, which functions as bridge to bring the 
target and E2 together. Regulation of degradation by SCF occurs by regulation of the 
phosphorylation of the substrates as well as regulated expression of F box proteins. 
The other key E3 ligase involved in the cell cycle is the APC, which is required to 
induce M phase progression and exit by mediating degradation of cell cycle regulators like 
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Pds1/securin and Cyclin A/B. APC is a large complex consists of at least 11 subunits 
including a catalytic core formed by a cullin-like protein, Apc2, and a Ring finger protein 
called Apc11. The targets of APC have conserved motifs that target them for ubiquitination. 
The most widespread motif is the so called Destruction box (D-box) with some version of an 
RXXL sequence. Another important motif is the Ken-Box with KENXXXN sequence. 
The activity of APC is controlled by binding of different activator subunits Cdh1 and 
Cdc20 which triggers APC ubiquitin ligase activity towards appropriate substrates during 
different cell cycle stages. At M phase, Cyclin/Cdk1 complexes phosphorylate core APC 
subunits and enhance Cdc20 binding. APC/Cdc20 targets securin for triggering sister 
chromatid separation and also inactivates Cyclin/Cdk1 by triggering Cyclin A and Cyclin B 
destruction (Shirayama et al., 1999). As a result of cyclin destruction at the end of mitosis, 
due to lack of Cyclin/Cdk1 activity, Cdc20 is released and APC/Cdc20 is no longer active 
(Peters, 2002). 
In contrast to the case with Cdc20, the Cyclin/Cdk activity inhibits binding of the 
other activating subunit Cdh1 to APC by phosphorylating Cdh1 throughout the S and M 
phases until the metaphase to anaphase transition where Cyclins are degraded by APC/Cdc20 
causing inactivation of Cdks (Kramer et al., 2000; Zachariae et al., 1998a; Blanco et al., 
2000). This allows Cdh1 dephosphorylation and interaction with APC, which keeps the 
APC/Cdh1 activity high during G1 until the next S phase.  Several S phase related proteins 
such as Cyclin A, Cdc6, Skp2 are targeted by APC/Cdh1 during G1(Harper et al., 2002). 
In human cells, there are six other cullin family proteins in addition to Cullin1. Also 
there is at least one more cullin-like protein, the PARkin-like cytoplasmic protein (PARC), in 
addition to Apc2 (Zachariae et al., 1998b; Yu et al., 1998; Nikolaev et al., 2003). Each of the 
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cullin family members nucleates a multisubunit E3 ligase complex that probably has a 
similar modular architecture as the SCF. All cullins associate with a RING protein (which is 
Roc1 for all cullins except Cullin 5 which prefers Roc2) through their C-terminal domain and 
the Roc1 protein recruits E2 to form the catalytic core, whereas the N-terminal region 
interacts with specific adaptor proteins to recruit a wide variety of receptor proteins that 
confer substrate specificity (Ohta et al., 1999). Each cullin has its own adaptor protein(s).  
While Cullin1 and 7 interact with Skp1, Cullin 2 and 5 interact with elongin BC, Cullin 3 
interacts with BTB domain containing proteins and Cullin 4 interacts with DBB1 (Michel 
and Xiong, 1998; Dias et al., 2002; Geyer et al., 2003; Furukawa et al., 2003; Wertz et al., 
2004).  The cullin adaptor complexes then interact with substrate binding proteins: Cullin 
1/Skp1 interacts with F box proteins, elongin BC interacts with suppressor of cytokine 
signalling/elongin-BC (SOCS/BC box) proteins (Bai et al., 1996; Kamura et al., 1998). In the 
case of Cul3, both adaptor protein and substrate receptor functions merged in the multiple 
proteins that bind to Cul3 via their N terminal BTB domain and to the substrate through their 
C-terminal domain (Geyer et al., 2003; Pintard et al., 2003; Xu et al., 2003; Furukawa et al., 
2003). 
The large number of F box, BTB-domain and SOCS/BC box proteins results in a 
huge number of potential Cullin E3 ligases that can target a wide variety of proteins which 
are potentially performing various cellular functions, including many related to cell cycle that 
are yet to be discovered. 
 
Translation control and cell cycle: 
 
 11
Proper cell cycle progression requires the expression and activation of key proteins at 
certain time periods. As explained above, transcriptional regulation or posttranslational 
regulations like phosphorylation and regulated degradation are very important for cell cycle 
progression. Recently, control of gene expression at the translation level has emerged as an 
essential and relatively poorly studied mechanism in cell cycle regulation.  Expression of the 
some the key players of cell cycle such as Cyclin D, Cyclin E, p27, p58, p53, Cdk4, SLBP 
have been shown to be controlled at the translation level (Cornelis et al., 2000; Millard et al., 
2000; Millard et al., 1997; Polymenis and Schmidt, 1997; Whitfield et al., 2000). 
In general, translational regulation may occur at two different levels: “global” control 
in which activity of translation machinery is regulated resulting in changes in translation 
efficiency of many cellular mRNAs, and “selective” control where translation of certain 
mRNAs is regulated specifically without affecting the general translation. 
Global translation regulation is mostly regulated at the translation initiation level by 
affecting the level and activity of initiation factors.  As mRNAs are exported from nucleus, 
the eukaryotic translation initiation multiprotein complex eIF4F assembles on the 5’Cap 
structure-m7GpppN (N is any nucleotide).  The eIF4F complex consists of 3 subunits: eIF4E 
(the cap-binding protein), eIF4A (an RNA helicase), and eIF4G which functions as scaffold 
protein that can interact with eIF4E and eIF4A and several other proteins like PABP (poly A 
binding protein) and Mnk1 (the eIF4E kinase) at the same time. It also interacts with the 40S 
subunit of the ribosome through eIF3. 
The activity and availability of eIF4E is regulated as an important mechanism to 
introduce global control on Cap-dependent translation which represents the majority of the 
translation in the cell. Generally the amount of active eIF4E is less than the number of 
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mRNAs in the cell, resulting in a competition between the mRNAs for the available eIF4E.  
Increasing the amount of active eIF4E thus results in the translation of several mRNAs which 
normally may compete poorly for eIF4E. eIF-4E is a phosphoprotein and its phosphorylation  
by the kinase called Mnk1 enhances the translation rate. Also there is a family of translation 
inhibitory proteins called eIF4E-binding proteins (4E-BPs), whose hypophosphorylated 
forms compete with eIF4G to bind same binding site on eIF4E that eIF4G binds.  High 
amounts of hypophosphorylated 4E-BP reduce the rate of Cap-dependent translation.  
Phosphorylation of the 4E-BPs prevents their binding to eIF4E, effectively increasing the 
concentration of active eIF4E, thus translation rate (Richter and Sonenberg, 2005). 
During the cell cycle, translation is regulated at the global level such that the 
translation level is robust to allow cells to progress through G1 and S-phase, and translation 
becomes low at M phase (Hay and Sonenberg, 2004; Pyronnet and Sonenberg, 2001). It has 
been shown that the MAP kinase and Tor kinase pathways are involved in the G1/S transition 
by affecting translation efficiency (Fukunaga and Hunter, 1997; Gingras et al., 2001; Burnett 
et al., 1998). mTor can directly phosphorylate and activate p70 S6 ribosomal kinase, 
P70S6K, which is particularly important for translation of special class of mRNAs with 5’ 
oligopyrimidine tract such as mRNAs of several ribosomal proteins and translation 
elongation factors. mTor also phosphorylates 4E-BP providing more active eIF4F. In 
addition to mTor, MAP kinase mediated phosphorylation and activation of Mnk1 is also 
important during G1 progression. Mnk1 is eIF4E kinase which also enhances translation.  
Activation of these pathways allows the cell to enhance the ribosome production that it will 
need for cell growth prior to cell division (Hay and Sonenberg, 2004). 
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Although the global regulation of translation effects translation of most of the 
mRNAs, it can end up with relatively specific effects on translation of certain mRNAs due to 
some cis-elements such as a secondary structure at their 5’UTR (Gingras et al., 1999) or 
upstream AUGs. These classes of mRNAs consist mostly of mRNAs encoding proteins 
related to cell growth and cell-cycle progression (e.g. the growth factor thrombopoetin, FGF2 
and Cyclin D1, c-myc)(Muise-Helmericks et al., 1998). Translation of these mRNAs is more 
sensitive to eIF4F assembly for example because of their higher need for the unwinding 
activity brought by eIF4A RNA helicase.  Thus increasing the concentration of active eIF4F 
in the cell specifically stimulates the translation of many mRNAs required for cell growth 
and cell cycle progression. 
During M phase general translation level diminishes significantly. At M phase, 4E-
BP is hypophosphorylated and this causes the disruption of the eIF4F complex and an overall 
low translation level. Although Cap-dependent general translation is inhibited during M 
phase, a subset of mRNAs are translated via cap independent translation where ribosomes are 
brought to mRNAs by an internal ribosome entry site (IRES) (without need for eIF4G 
complex), which is considered as mechanism of cell cycle dependent translation control on 
expression of certain proteins. 
In addition to global translation regulation, selective regulation mostly occurs by 
recognition of specific cis-elements in the target mRNAs by specific proteins or miRNAs. 
For example, as a critical cell cycle protein, translation of p27 mRNA is regulated by binding 
of RNA binding proteins HuR and hnRNP C1, C2, which interact specifically with U-rich 
element in its 5’UTR (Millard et al., 2000).  As example for translation inhibition by 
miRNAs, specific miRNAs has been determined to target 3’UTRs and inhibit translation of 
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the important cell cycle proteins such as E2F1, c-myc and p27 (O'Donnell et al., 2005).  The 
regulation of translation by miRNAs is a rapidly developing field and the large numbers of 
miRNAs have the potential to regulate a large number of mRNAs. The selective translation 
control, as a mechanism of regulation of several critical cell cycle proteins, is becoming an 
important but yet understudied control mechanism during cell cycle. 
 
S PHASE: REPLICATION OF CHROMOSOMES 
 
In eukaryotic cells, the DNA in the chromosomes is highly packaged into a DNA-
protein assembly called chromatin. The chromatin structure is composed primarily of 
histones and as well as non-histone proteins.  The chromatin structure is not only important 
for DNA packaging which is required for genomic stability but also is very important for 
regulation of gene expression. 
During each S phase, eukaryotic cells must not only replicate their DNA, but must 
also assemble the chromatin structure in each daughter chromosome properly.  The first step 
in chromosome assembly is to assemble new nucleosomes on the newly synthesized DNA.  
This requires a rapid production of for raw materials, namely histone proteins to package 
newly replicated DNA into nucleosomes. In metazoans, a unique set of genes, the replication 
dependent histone genes, which are primarily expressed in S phase, encode the majority of 
histone proteins. These mRNAs have several unique properties which distinguish them from 
the rest of the eukaryotic mRNAs, and they require a distinct set of factors for many aspects 
of their expression and regulation (Marzluff, 2005). A minority of the histone proteins, the 
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so-called replacement variant histones, are constitutively expressed at low rate from 
polyadenylated mRNAs, which are metabolized like rest of the eukaryotic mRNAs. 
 
Replication dependent histone genes and cell cycle regulation: 
 
In all metazoans, replication dependent histone genes have distinct characteristics: 
first, they lack introns, second they are physically linked in large clusters, and finally they 
encode unique mRNAs which don’t have polyA tails but instead they end in a highly 
conserved 26 nucleotides sequence with a stem loop structure. Other than 5’ capping, the 
only processing step necessary to produce mature histone mRNA is endonucleolytic cleavage 
after 3’ stem loop structure (Gick et al., 1986; Dominski and Marzluff, 1999). This cleavage 
reaction requires two cis-elements, the stem loop structure and the purine rich element called 
the histone downstream element (HDE) which binds to the U7snRNP (Mowry and Steitz, 
1987; Mowry et al., 1989; Cotten et al., 1988). Along with the U7snRNP, a 31 kD protein 
called stem loop binding protein (SLBP) that binds to stem loop structure, is required for 
histone mRNA processing. 
The HDE interacts with U7 snRNP which is a small nuclear ribonucleoprotein 
(snRNP), by base pairing with 5’end of U7 snRNA.  In addition to the HDE complementary 
site, U7 snRNA has a unique Sm binding site that recruits 7 Sm-proteins, five of which are 
shared with spliceosomal snRNPs, and two novel proteins, Lsm10 and Lsm11 which are 
likely to be restricted to U7snRNP.  In mammals, U7snRNP contains an additional protein 
called ZFP100 that interacts both to SLBP and stem loop complex and Lsm11, possibly 
bridging the Stem loop structure with the U7snRNP.  The Cleavage reaction occurs between 
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the stem loop structure and HDE by a complex that contains CPSF-73 and several other 
factors that are known to play a role in polyA mRNA maturation (Dominski et al., 2005). 
Replication dependent histone mRNAs are tightly cell cycle regulated. As cells 
progress G1 to S phase the level of histone mRNAs increase 35 fold and decrease back to the 
same amount at the end of S phase (Harris et al., 1991). Most of this regulation is done by 
posttranscriptional mechanisms which are mediated by stem loop structure (Pandey and 
Marzluff, 1987; Marzluff and Pandey, 1988). As cells enter S phase, the transcription of 
histone genes increases only 3 to 5 fold and as major regulatory step, pre-mRNA processing 
efficiency increases 10 fold, and together these account for the 35 fold increase in histone 
mRNA level. At the end of S phase, histone mRNA processing is inhibited and the half life 
of histone mRNA is reduced to 10 minutes (Harris et al., 1991). 
A major component of this regulation is the cell-cycle regulation of the key player 
SLBP, which is synthesized just before entry into S-phase and rapidly degraded at the end of 
S-phase, effectively regulating histone pre-mRNA processing, in vivo (Zheng et al., 2003).  
SLBP appears to be the only factor involved in histone mRNA processing that is cell cycle 
regulated. It is the sole player needed for processing that is absent in G1 and G2 nuclear 
extracts. 
Although both histone mRNA and SLBP are regulated in parallel during the cell 
cycle, the signals regulating their expression differ. Although stability of histone mRNAs is 
directly coupled to DNA replication, SLBP expression is controlled most probably by cell 
cycle signals and is not affected by the status of DNA replication.  When G1 cells are treated 
with aphidicolin, SLBP accumulates normally after cells commit for S phase. However, 
histone mRNA levels never increase. In parallel with that observation, when we treated cells 
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with DNA replication inhibitor, hydroxyurea, histone mRNA level rapidly go down while the 
SLBP level remains constant.  Finally, when SLBP degradation is blocked at the end of S 
phase, histone mRNA levels go down normally when replication is completed. 
SLBP is the key player in histone mRNA metabolism, participating in multiple steps 
of histone mRNA metabolism. After the processing, SLBP stays on the histone mRNA and is 
involved in both translation and mRNA stability (Wang et al., 1996; Dominski et al., 1999; 
Sanchez and Marzluff, 2002). Consistent with its role in histone mRNA synthesis and 
translation, when SLBP levels are knocked down by RNA interference, the rate of 
progression through S-phase is greatly slowed (Wagner et al., 2005).  In contrast U7 snRNP 
is present constitutively during the cell cycle, and the limiting factor for histone pre-mRNA 
processing is the presence of SLBP. 
 
Cell cycle regulation of SLBP- the key player in histone mRNA metabolism: 
 
The SLBP level is quite low at G1 and it dramatically increases as cells enter S phase. 
It has been shown that the low level of SLBP at early G1 is due to the low translation 
efficiency of SLBP mRNA and as cells approach S phase the translation of SLBP is activated 
(Whitfield et al., 2000).  At the end of S phase, SLBP levels drop due to rapid degradation by 
the proteosome. The degradation of SLBP at S/G2 requires two threonines and proline 
residues in the N-terminal SFTTP motif and a downstream KRKL motif which is a putative 
Cyclin binding site. Previous work by Lianxing Zheng has shown that both of the threonines 
get phosphorylated by different kinases and trigger late S phase SLBP degradation. 
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In this dissertation, I have further elucidated the molecular details of the mechanisms 
involved in cell cycle regulation of SLBP expression.  In the second chapter, I showed that 
Cyclin A/Cdk1 triggers degradation of SLBP by phosphorylating Thr 61 and this is one of 
the mechanisms to shut down histone mRNA biosynthesis at the end of S phase. In the third 
chapter, I have tried to determine the mechanisms involved regulating low level of SLBP at 
G1. I have shown that SLBP coding sequence is sufficient to introduce low translational 
efficiency of SLBP mRNA as a regulation to keep the SLBP protein level low at early G1. I 
also provide evidence that after certain point in G1, SLBP translation efficiency recovers 
back to S phase level but SLBP protein level kept low until S phase possibly by controlled 
proteindegradation.
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CHAPTER II: 
Cyclin A/Cdk1 Triggers Degradation of SLBP At The End of S Phase by 
Phosphorylating Thr 61. 
 
INTRODUCTION 
 
Progression through the cell cycle is driven by a class of protein kinases, the cyclin-
dependent kinases (Cdks), which are sequentially activated and deactivated as cells progress 
from one cell cycle stage to the next.  In particular, progress into S-phase requires the 
activation of Cyclin E/Cdk2, ultimately resulting in the initiation of DNA replication, and 
progression through mitosis requires the activation of Cyclin B/Cdk1 resulting in nuclear 
envelope breakdown and chromosome condensation (Sanchez and Dynlacht, 2005).  Cyclin 
A/Cdk2 activity is required for continued progression through S-phase (Yam et al., 2002).  
The targets of the cdks are activated or inactivated by phosphorylation.  A second critical 
regulatory mechanism for cell cycle progression is targeted proteolysis of key protein 
regulators (Hoyt, 1997). These include the cyclin subunits of the Cdks, critical proteins in 
initiation of DNA replication, and proteins responsible for maintaining chromosome pairing 
(Clarke, 2002). 
While much is known about the events that occur for cells transition from G1 to S-
phase and for cells to enter and exit mitosis, much less is known about molecular events at 
the end of S-phase, as cells progress from S to G2-phase.  S-phase is characterized by 
replication of the chromosomes, and in addition to DNA replication, there must be extensive 
histone protein synthesis to provide the histones for assembly of the newly replicated 
chromatin.  Histone mRNAs are cell-cycle regulated and their expression is restricted to S-
phase.  The metazoan replication-dependent histone mRNAs are the only eukaryotic mRNAs 
that are not polyadenylated.  Instead they end in a conserved stem-loop sequence (Marzluff, 
2005).  Since the replication-dependent histone genes lack introns, the only processing 
reaction required for histone mRNA biosynthesis is cleavage of the nascent transcript to form 
the 3’ end of the mRNA (Marzluff, 2005).   
The 3’ end of histone mRNAs is a major cis element responsible for the coordinate 
regulation of histone mRNA levels (Lüscher et al., 1995).  The 3’ end is bound by the stem-
loop binding protein (SLBP) which is required for both histone pre-mRNA processing and 
histone mRNA translation.  The processing of histone pre-mRNA is cell-cycle regulated, as 
is the stability of histone mRNAs (Harris et al., 1991).  SLBP is also a cell-cycle regulated 
protein, accumulating only in S-phase cells, and regulation of SLBP levels is an important 
component of the cell-cycle regulation of histone mRNA (Whitfield et al., 2000).  SLBP is 
rapidly degraded at the end of S-phase, as a result of phosphorylation of two threonines in an 
SFTTP sequences (amino acids 58-62).  Proline 62 is also required for SLBP degradation as 
is a KRKL sequence (amino acids 95-98) (Zheng et al., 2003),  that is a consensus cyclin 
binding site (Loog and Morgan, 2005; Archambault et al., 2005; Adams et al., 1996; Adams 
et al., 1999; Schulman et al., 1998; Brown et al., 1999). 
I show here that Cyclin A/Cdk1 triggers SLBP degradation at the end of S phase by 
phosphorylating Thr61.  Cyclin A/Cdk1 activity is cell cycle regulated similar and is the 
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major activity in late S-phase cells that phosphorylates Thr 61 of SLBP.  We propose that 
Cyclin A/Cdk1 is activated near the end of S-phase resulting in degradation of SLBP and 
down regulating histone mRNA synthesis.  It is likely that Cyclin A/Cdk1 phosphorylates 
other targets at the same time, helping the cell transition from S-phase to G2-phase. 
RESULTS 
 
Cyclin/Cdk is involved in degradation of SLBP at S/G2 transition. 
SLBP expression is limited to S phase (Whitfield et al., 2000). At the end of S phase, 
SLBP is rapidly degraded (Fig. 1A, B). Previously, we have shown that SLBP degradation 
requires phosphorylation of two threonine residues Thr 60, 61 by two different kinases 
(Zheng et al., 2003). Further, we have shown that along with Thr60 and Thr61, proline 62 
and a downstream KRKL region is required for SLBP degradation at the end of S phase 
(Zheng et al., 2003). The fact that TP (Thr 61, Pro 62) is a possible Cdk target site and 
KRKL is a putative cyclin binding site suggests that a Cyclin/Cdk is involved in SLBP 
degradation by phosphorylating Thr61. To test this possibility, I examined the affects of 
roscovitine, a known Cdk1/Cdk2 specific inhibitor, on SLBP degradation at S/G2 in Hela 
cells. At G2, SLBP level remained relatively high in cells treated with roscovitine in 
comparison to DMSO treated control cells (Fig. 2A). FACS analysis confirmed that both cell 
populations successfully completed S phase and accumulated at G2.  There was not a 
significant difference in their cell cycle profile at the time of collection (Fig. 2B). Since 
roscovitine is specific to Cdk1/Cdk2, we hypothesized that one or both of these Cdks is 
involved in SLBP degradation possibly by phosphorylating Thr 61. Several other kinase 
 22
inhibitors were tested at late S phase, however none of these inhibitors except roscovitine and 
inhibitors of CKII (see Fig. 13) showed inhibitory effects on SLBP degradation (Table 1). 
In order to determine whether phosphorylation of these two residues is sufficient to 
trigger SLBP degradation, I designed a GST protein SLBP fragment (aa 51-108) chimera 
protein in which all of the phosphoacceptor sites except these two threonines are mutated to 
alanine (Fig 3). I cloned this fusion protein into the myc- tagged pcDNA3 vector and stably 
expressed this protein in HeLa cells. Next, to analyze the regulation of expression of this 
chimeric protein, cells were synchronized by double thymidine block and collected cells at S 
phase (3 hrs after release) and G2/M (9 hrs after release) (Fig. 4).  The chimeric protein was 
degraded at G2 in parallel with the endogenous SLBP (Fig. 4, lane 1and lane 2). To confirm 
that the GST SLBP fragment was degraded by a similar mechanism as full length SLBP, I 
mutated Thr61 to alanine in the GST SLBP fragment. The GST SLBP fragment containing 
this mutation was stable at the end of S-phase (Fig. 4, lanes 3 and 4) and the same mutation 
of Thr61 to alanine in the full length SLBP also prevented SLBP degradation at the end of S-
phase (Zheng et al., 2003). 
Next, I expressed the GST-SLBP fusion protein fragment (51-108 aa) in bacteria that 
is sufficient and required for S/G2 degradation and used the recombinant protein as a 
substrate for in vitro kinase assays (Fig. 5). I also constructed and expressed the mutant 
forms TAP, ATP in the TTP (aa 60-62) sequence and a mutant with the KRKL sequence 
changed to 4 alanines (Fig. 3, 5).  I prepared an extract from late S-phase cells (6hrs after 
release from double thymidine block) and used this extract as a source of kinase activity. The 
extract phosphorylated the wild-type TTP (Fig. 5, lane 1), and ATP protein but not the TAP 
mutant or GST protein (Fig. 5, lanes 3 and 4).  These results suggest that Thr 61 is the only 
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site phosphorylated in this lysate. The activity was sensitive to roscovitine, demonstrating 
that this phosphorylation is mediated by Cdk1 or Cdk2 (Fig. 5, lane 2). 
 
Timing of in vitro phosphorylation of Thr61 corresponds to the time of SLBP 
degradation. 
In order to determine whether the kinase activity responsible for the Thr 61 
phosphorylation was regulated during the cell cycle, I performed in vitro kinase assays using 
the bacterially expressed SLBP fragment as a substrate and lysates from HeLa cells isolated 
at different time points of cell cycle as the kinase source. I tested extracts prepared 4, 6, 10, 
11, 12, and 14 hours after release from thymidine block.  These cell cycle points correspond 
to G1/S (0 hrs), mid-S phase (4 hrs), S/G2 (6 hrs), M/G1 (10, 11 hrs), early and mid G1 (12 
and 14 hrs). With TTP SLBP Fragment, I detected peak phosphorylation at late S phase 
(S/G2) overlapping the point where SLBP degradation started (Fig 6A). I did not detect 
significant phosphorylation using lysates from G1 or G1/S cells. With TAP SLBP substrate, I 
could not detect phosphorylation suggesting that the phosphorylation I detected is on Thr 61. 
Since we have previously shown that in vivo, the KRKL region is required for both Thr61 
phosphorylation and SLBP degradation at S/G2, I tested the phosphorylation of KRKL/4A 
SLBP Fragment and I showed that in the absence of KRKL sequence I detected almost no 
phosphorylation in S and S/G2 lysates and some phosphorylation using an M-G1 phase 
lysate (Fig 6B).  Addition of roscovitine to the in vitro kinase assays, abolished the 
phosphorylation of the SLBP Fragment as well as the residual phosphorylation of KRKL/4A, 
suggesting all Thr 61 phosphorylation including the residual phosphorylation of KRKL/4A 
mutant in the M-G1 extract, was mediated by a Cyclin/Cdk (Fig 6B). 
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Next, we have concentrated on S phase only and repeated the same kinase assays with 
different time points throughout the S phase. We detected phosphorylation peaking at late S 
phase (S/G2) where SLBP is gone (Fig. 7). We detected phosphorylation on GST SLBP 
fragments TTP and ATP but not TAP, showing that the phosphorylation we detected 
occurred on Thr61 (Fig 7). Interestingly, although phosphorylation on Thr 61 has 
significantly increased at S/G2, there is no significant increase in the phosphorylation of H1, 
indicating that in this experiment the cells had not reached the point at G2/M where Cyclin 
B/Cdk1 activity rapidly increases. 
 
            Cyclin A/Cdk1 phosphorylates SLBP on Thr 61 
In order to determine whether Cdk1 or Cdk2 was the major kinase responsible for late 
S phase phosphorylation of Thr 61, I performed immunodepletion experiments using late S 
phase lysates and cdk1 or cdk2 antibodies. In the case of Cdk2 depletion, although most of 
the Cdk2 was removed (Fig 8, lane 2), there was no significant difference in Thr61 
phosphorylation detected. On the other hand, removal of even 30-40% Cdk1 from the lysate, 
significantly reduced the phosphorylation of Thr 61 suggesting that Cdk1 was the major 
kinase that is responsible for the phosphorylation detected in vitro (Fig 8). Mock depletion 
using the protein A beads alone had no effect on the kinase activity, or on the levels of cdk1 
or cdk2. 
Next, to determine the ability of different Cyclin/Cdks to phosphorylate SLBP Thr 
61, I immunoprecipitated Cyclin A and Cyclin B complexes and Cdk2 or Cdk1 from late S 
phase lysates and tested their ability to phosphorylate GST-SLBP Fragment.  With the 
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substrates that I used, I only detected phosphorylation on the ones with SLBP TTP (wildtype) 
but not TAP confirming that I am detecting phosphorylation on Thr61 of SLBP (Fig 9). 
In order to determine the Cyclin partner, I immunoprecipitated Cyclin A/Cdks and 
Cyclin B/Cdks with anti cyclin A or anti cyclin B and tested those kinase complexes for the 
ability to phosphorylate SLBP on Thr 61 using substrates with a wild type KRKL sequence 
or a 4A mutation (Fig 9A). Cyclin A/Cdk required the KRKL region to phosphorylate Thr61 
(Fig. 9A).  However, Cyclin B/Cdk immunoprecipitates phosphorylated the substrates with 
or without the KRKL to a similar extent.  Thus the cyclin B kinases are likely not the kinases 
that are responsible for Thr 61 phosphorylation, in vivo. 
I compared the ability of the Cyclin/Cdk2 complexes and the Cyclin/Cdk1 complexes 
from the same extracts to phosphorylate both SLBP Fragment and histone H1, and 
normalized the SLBP Thr 61 kinase activity of each immunoprecipitate to the activity seen 
with histone H1 as a substrate.  I have showed that Cyclin/Cdk1 phosphorylates SLBP Thr 61 
much more efficiently than Cyclin/Cdk2. The Cdk2 immunoprecipitates phosphorylated the 
SLBP fragment only 1/3 as efficiently as they phosphorylated histone H1 (Fig. 9B, lanes 1 
and 3).  The activity on SLBP was completely dependent on the KRKL sequence.  In 
contrast, the Cdk1 immunoprecipiates phosphorylated the SLBP fragment better than they 
phosphorylated histone H1 (Fig. 9B, lanes 5 and 7).  The great majority of this activity by 
Cdk1 was dependent on the KRKL sequence, too. When I normalized their ability to 
phosphorylate Thr61 to H1, I found that Cdk1 can phosphorylate the SLBP substrate much 
more efficiently (3-4 times) than Cdk2.  This result is consistent with the  interpretation that a 
Cyclin/Cdk1 is the kinase that phosphorylates SLBP on Thr61 and triggers its degradation at 
late S phase. 
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The Cdk1 complexes that could be present in the cell are either Cyclin A/Cdk1 and 
Cyclin B/Cdk1, and Cyclin B/Cdk1 is likely to be the only Cyclin B /Cdk complex. Since 
most of the Cdk1 activity that phosphorylates Thr 61 is dependent on the KRKL sequence, 
this activity must be mostly due to Cyclin A/Cdk1 (Fig, 9A, lanes 5 and 6) but not Cyclin 
B/Cdk1. When it comes to Cdk2, it can be in a complex with both Cyclin A and Cyclin E. 
Since Cyclin E level is high at early S and has already dropped at S/G2 (Dulic et al., 1992), 
cyclin A/Cdk2 is most of the Cdk2 activity we detected with Cdk2 immunoprecipitates (Fig 
9B, lane 1).  
In conclusion, I conclude that Cyclin A/Cdk1 is the major kinase that phosphorylates 
Thr 61 depending on KRKL sequence in S/G2 cells. 
Knocking down Cdk1 results in stabilization of SLBP 
To further examine the role of Cdk1, we knocked down Cdk1 in synchronized HeLa 
cells using a Cdk1 specific RNAi (Fig. 10).  Using the strategy shown in Fig. 10A, where 
siRNA treatment was combined with double thymidine block, we have been able to 
knockdown a number of proteins in synchronized cells.  Control cells were treated with the 
same siRNA protocol using a control, C2, siRNA (Wagner and Marzluff, 2006). The levels 
of Cdk1 protein were reduced about 70% by the RNAi treatment.  Six hrs after release from 
the thymidine block, the cells were in late S-phase.  As shown at Fig. 10B, there was less 
SLBP degradation at late S phase when Cdk1 is knocked down compared with the control 
cells.  FACS analysis of these cells that the cell cycle distribution of the cells was 
comparable in the treated and control cells (Fig 10C). 
Timing of the SLBP degradation does not depend on Thr60 phosphorylation. 
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Previously we showed that changing either Thr60 or Thr61 to alanine stabilized 
SLBP.  Lianxing Zheng had created some possible phosphorylation mimics, none of which 
resulted in an SLBP that was properly regulated.  I further attempted to mimic 
phosphorylations by creating SLBPs containing SFDTP and SFETP in place of SFTTP, and 
then selected populations of cells stably expressing the mutant SLBPs at a similar level to the 
wild-type SLBP.  The SFDTP mutant was stable at the end of S-phase, indicating that the 
aspartic acid did not mimic the phosphothreonine (Fig. 11A, bottom).  However, the SFETP 
mutant was regulated properly (Fig. 11A top) and was degraded like stably expressed wild 
type SLBP, a little slower than endogenous SLBP but yet still unstable at G2.  Treatment of 
the cells at late S phase with the proteosome inhibitor MG132 stabilized the endogenous 
SLBP as well as the SFETP SLBP (Fig. 11A, lane 4).  This result demonstrates that the E at 
position 60 mimics phosphothreonine, and likely targets SLBP to the proteosome when T61 
is phosphorylated.  Since the SFETP SLBP is expressed at normal levels during S-phase and 
then degraded, I conclude that phosphorylation of Thr61 is essential for proper timing of the 
degradation of SLBP. It has been shown that Cyclin A/Cdk1 is getting activated near the end 
of S-phase (Pagano et al., 1992; Mitra et al., 2006).  The mutagenesis data taken together 
with my biochemical results implicate Cyclin A/Cdk1 as the kinase that phosphorylates 
Thr61 of SLBP, and that this phosphorylation is necessary to trigger degradation of SLBP at 
the end of S phase. 
 
CKII may be the kinase that phosphorylates Thr60. 
The identity of the kinase that phosphorylates the other threonine, Thr60, also 
required for S/G2 SLBP degradation still remains as a question. Unfortunately, under my 
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conditions I could not detect any phosphorylation of Thr 60 with my cell lysates (Fig 4, 6).  
Therefore, I have taken a bioinformatic approach and searched for kinase(s) that have target 
consensus sequences with similarity to the sequence flanking Thr 60 in SLBP. As candidate 
kinase, CkII is known to target a consensus motif with n+1 and/or n+3 negative charges from 
either E/D or phosphoT/S (Wojda, 2000).This consensus fits quite well SLBP TTPE 
sequence where n+1 could be a phosphothreonine and n+3 is a negatively charged glutamic 
acid.  
Based on this analysis, I tested two different commercial CKII inhibitors, TBB and 
DMAT, and added them to mid-S phase cells.  Each of these inhibitors inhibited S/G2 
degradation of SLBP to a certain extent (Fig. 13).  For the next experiment, I reasoned that if 
SLBP degradation block by CKII inhibitors is a result of preventing Thr60 phosphorylation, 
the Thr60E phosphomimic should rescue the blocking effect of CKII inhibitors on SLBP 
degradation. When I treated HeLa cells stably expressing his tagged-T60E SLBP with CKII 
inhibitor at mid- S phase, degradation of both the endogenous and exogenous SLBP were 
inhibited (Fig 14A). The finding that Thr60E phosphomimic can not rescue the stabilizing 
effect of CKII inhibitors, suggests that CKII may be required for SLBP degradation at some 
other step than phosphorylation of SLBP. Even if CKII is required for an additional step in 
SLBP degradation, this doesn’t exclude the possibility that it is also functioning as Thr60 
kinase.  
Finally, I have mutated negative charged Glu63 at n+3 position to alanine to check 
whether it is required for SLBP degradation. When I synchronized HeLa cells that are stably 
expressing his-tagged E63A SLBP, this mutation didn’t stabilized SLBP at G2 but yet 
degradation rate appears to be quite slower than wild type SLBP (Fig. 14B). 
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DISCUSSION 
 
Among the cell cycle stages, molecular events at late S phase and S/G2 transition, 
where major S phase events-DNA replication and rapid production of new histone proteins- 
are completed, are may be the least understood. Here, I introduce a cell cycle signaling 
mechanism that occurs at the end of S phase where Cyclin A/Cdk 1 induces an inhibitory 
signal on histone mRNA biosynthesis by triggering degradation of SLBP which is the key 
and only cell cycle regulated player in histone mRNA metabolism. I believe that Cyclin 
A/Cdk1 may be the kinase that also regulates several other events at S/G2 transition.  
 
Thr 60 and Thr 61 phosphorylations mediates SLBP degradation at S/G2. 
We have previously shown that phosphorylation of Thr 60 and Thr 61 by different 
kinases are required for SLBP degradation at S/G2.  Along with those thereonines a proline 
residue just near Thr 61 (proline 62) and a downstream putative Cyclin binding site (KRKL) 
is required for SLBP degradation. We also have shown that T61 phosphorylation and 
degradation requires a downstream putative Cyclin binding site, KRKL.    
By stable expression of GST fused SLBP fragment containing both thereonines and 
KRKL region but all other possible phosphoacceptor sites (thr and serines) changed to 
alanine, I have shown that phosphorylation of these threonines are not only required for 
SLBP degradation at S/G2 but also constitutes sufficient phosphorylation signal for SLBP 
degradation at the end of S phase (Fig 4).  
 
Cyclin A/Cdk1 triggers degradation of SLBP at S/G2. 
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The TP motif and requirement of a downstream KRKL region which is putative 
Cyclin binding site (RXL) suggested a Cyclin/Cdk involvement in SLBP degradation by 
phosphorylating Thr 61. In support of this idea, I have shown that treatment of Cdk1/Cdk2 
inhibitor at late S phase cells inhibits SLBP degradation at S/G2.  Further using my GST 
SLBP fragment as a substrate in in vitro kinase assays, I have shown significant Thr 61 
kinase activity appeared at S/G2 border where SLBP degradation starts. I also confirmed that 
this Thr 61 phosphorylation is Cdk mediated (roscovitine sensitive) and requires downstream 
KRKL region just as in the in vivo situation.   
Based on pattern of Thr 61 kinase activity, we concluded that Cyclin E/Cdk2 is very 
unlikely to be the Thr 61 kinase since Cyclin E/Cdk2 activity peaks at early S and goes down 
at late S phase which is just opposite of the Thr 61 activity pattern that we detect. Among the 
possible Cyclin/Cdks known to be functioning at these cell cycle stages, I investigated the 
possible role of cyclin/cdk1 and cyclin/cdk2 kinases. 
When I compared the Thr 61 phosphorylation ability of Cyclin A/Cdk and Cyclin 
B/Cdk, I showed that Cyclin A/Cdk but not Cyclin B/Cdk requires the downstream KRKL 
region. Since we know that in vivo both Thr 61 phosphorylation and SLBP degradation 
requires KRKL region, I conclude that a Cyclin A/Cdk but not Cyclin B/Cdk is the kinase 
that phosphorylates Thr 61 in vivo. 
Our results strongly suggest that a Cyclin A/Cdk is triggering SLBP degradation at 
the end of S phase by Thr 61 phosphorylation, and further experiments support the 
conclusion that Cyclin A/Cdk1 is the major kinase that phophorylates Thr 61 and triggers 
SLBP degradation.  The Thr 61 phosphorylation profile we detected fits very well with 
Cyclin A/Cdk1 activity which increases towards late S phase with a gradual increase toward 
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the point it peaks at G2 (Pagano et al., 1992; Mitra et al., 2006). With immunodepletion 
experiments, I confirmed that majority of the Thr 61 kinase activity detected in late S phase 
lysate is performed by Cdk1 instead of Cdk2. Also, I have shown Cyclin/Cdk1 
immunoprecipitated from late S phase phosphorylates Thr 61 in the SLBP fragment 
significantly more efficiently than Cyclin/Cdk2 obtained from same lysate and since the 
phosphorylation by Cyclin/Cdk1 complex mostly requires KRKL region we conclude that 
Cyclin A/Cdk1 (but not Cyclin B/Cdk1) is the kinase that is responsible for most of the Thr 
61 phosphorylation we detect with Cdk1 immunoprecipitates. Finally, fitting with our 
conclusion, that Cyclin A/Cdk1 is the kinase that phosphorylates Thr 61 and triggers SLBP 
degradation, Cdk1 knock down introduces inhibitory effect on SLBP degradation at the end 
of S phase.  
In summary, it seems that SLBP uses RXL motif to recruit Cyclin A but its non-
perfect Cdk2 target sequence around Thr 61 requires Cdk1 for full phosphorylation. This 
may be the case for several other Cyclin A/Cdk mediated events which waits until G2 
although there is high Cyclin A/Cdk2 activity throughout S phase. 
 
Cyclin A/Cdk1 activity is likely the determinant of timing of SLBP degradation. 
I have tried to mimic the Thr60 and Thr 61 phosphorylation by phosphomimic 
residues. I successfully mimicked Thr 60 phosphorylation since T60E SLBP is degraded at 
G2 similar to endogenous SLBP. Since in this mutant SLBP, Thr 60 phosphorylation is not 
regulated, (since I mimic the phosphorylation constitutively), it seems that Thr61 
phosphorylation determines the timing of SLBP degradation at G2. According to my model, 
as CyclinA/Cdk1 activity reaches to a significant critical level at S/G2 border, it 
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phosphorylates SLBP at Thr 61 to trigger SLBP degradation (Fig 12).  Whether Thr60 is 
constitutively phosphorylated during S-phase (or whether phosphorylation of Thr 60 is 
normally induced by phosphorylation of Thr 61) is not clear.  Once SLBP is phosphorylated, 
the adaptor which recognizes doubly phosphorylated SLBP and directs in degradation is not 
known. It is possible that this factor is also cell-cycle regulated.  
   
 Possible role of CKII in SLBP degradation.  
I have identified CKII as a candidate kinase that could target Thr 60 based on the 
sequence flanking the phosphorylation sites in SLBP. Consensus CKII target site is with a 
negative charge at n+1 and/or n+3 residues which is consistent with the sequence flanking 
Thr 60 in  SLBP, which has phosphothreonine at n+1 and a glutamic acid at n+3 position 
(Wojda, 2000).  Thus it is possible that phosphorylation of Thr 61 is necessary for efficient 
phosphorylation of T60 by casein kinase II.    
To test for a role of CKII I treated late S phase cells with two different commercial 
CKII inhibitors.  Both of these inhibitors blocked the degradation of SLBP at the S/G2 border 
(Fig. 13).   
On the other hand, since the degradation of SLBP containing the T60E 
phosphomimic is also sensitive to the CKII inhibitors, CKII must have some other effect on 
SLBP degradation. As one possible indirect effect, inhibition of CKII may affect the Cyclin 
A/Cdk1 activity which is the kinase for the other phosphorylation required for SLBP 
degradation. In parallel with that, it has been shown that CKII is involved in Cyclin/Cdk1 
activation as one of the signals that triggers Wee 1 degradation (Watanabe et al., 2005). 
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In conclusion, at this point it is difficult to assess whether CKII is directly involved in 
SLBP degradation as a kinase for Thr 60 and/or via an indirect role such as activating Cyclin 
A/Cdk1 activity.  
 
Cell Cycle regulation of SLBP and histone biosynthesis. 
SLBP is the sole factor involved in histone mRNA processing that is not present other 
than S phase.  Along with regulation of histone mRNA transcription and stability, cell cycle 
regulation of SLBP is one of the mechanisms that control histone mRNA biosynthesis and 
thus histone production to the S phase.  We haven’t detected any obvious phenotype due to 
the presence of stable SLBP at G2 in our experiments. Since we have used HeLa cells, it is 
very possible these transformed cells can survive excess amount of histones outside the S 
phase. Moreover, there are other mechanisms to regulate cell cycle dependent SLBP 
expression and also to limit the histone production to S phase.    
Other than TTP sequence mediated degradation at S/G2, at G1 until the next S phase, 
SLBP level kept low by different mechanisms ((Whitfield et al., 2000), and Koseoglu and 
Marzluff , unpublished data) such as low translational efficiency which may decrease the 
need for SLBP degradation at S/G2 border.  Also, more importantly, cells use several 
different mechanisms to limit excess histone production to the S phase including the low 
stability of histone mRNAs outside S phase. I believe as well as the redundancy of these 
different mechanisms, some mechanisms may be more critical at various times in the cell 
cycle or during development.     
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Table 1: List of kinase inhibitors analyzed for their effect on SLBP S/G2 degradation. 
HeLa cells were treated with indicated inhibitors (10µM final) or DMSO at 4 hours after 
double thymidine block for another 4 hours. SLBP levels were determined by western blot 
analysis using SLBP antibody.  
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Inhibitor Target  Stable SLBP 
at G2 
Roscovitine Cdk1, Cdk2         + 
Wortmanine PI3 Kinase         - 
PD 98059 MEK 1         - 
SB 202190 p38 MAPKs         - 
SB 203580 p38 MAPKs         - 
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Figure 1: SLBP expression during cell cycle A) Western blot analysis of SLBP expression 
in HeLa cells collected at indicated time points after release from double thymidine block. B) 
FACs analysis of the cells collected at indicated times after the release.  
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Figure 2: S/G2 degradation of SLBP is Roscovitine sensitive. A) Western blot analysis of 
SLBP level in HeLa cells which were treated with either dimethylsulfoxide (DMSO) or 
20microM Roscovitine (Ros) in DMSO after 4 hours after release from double thymidine 
block for 4 more hours. B) FACs analysis of both Ros and DMSO treated cells at the time of 
collection at A. 
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Figure 3: SLBP Fragment (aa.51-108) that is designed as substrate for kinase assays. 
Regions that are required for late S phase degradation are shown underlined. Possible 
mutations that have been introduced to those regions were introduced above the wild type. 
Ser/Thrs have been changed to alanine has been shown by A below the wild type sequence.  
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Figure 4: SLBP Fragment with only two phosphoacceptor sites (Thr61/Thr62)  is 
sufficient to introduce cell cycle dependent degradation, in vivo. HeLa cells stably 
expressing mycGST-SLBP fragment with wt TTP or TAP, were synchronized by double 
thymidine block and collected at S (4hrs after release) or G2 (9 hrs after release) phase. The 
level of mycGST-SLBP Frag. and endogenous SLBP were detected by western blot analysis 
using anti-myc and anti-SLBP antibody. 
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Figure 5: SLBP Fragment is phosphorylated on Thr 61 by a Cyclin/Cdk. In vitro kinase 
assays with bacterially expressed GST-SLBP Fragment (TTP, ATP, TAP) or GST alone were 
performed in the presence of γ32P ATP, using lysate from late S phase cells. The effect of 
Roscovitine (Cdk1/Cdk2 inhibitor,10microM) on phosphorylation was also determined. 
Samples were run on SDS PAGE and phosphorylation level of each substrate was 
determined by autoradiography. 
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Figure 6: Peak KRKL dependent and roscovitine-sensitive phosphorylation was 
detected with late S phase lysate. A) In vitro kinase assays were performed in the presence 
of γ32P ATP, using lysates from HeLa cells collected at indicated time points after the 
double thymidine block (panel 1). Samples were run on SDS PAGE and phosphorylation 
level of each substrate was determined by autoradiography (panel 1). Levels of SLBP and 
Cyclin A proteins in the lysates were examined by western blot analysis using anti-SLBP and 
anti-CycA antibody (panel 2,3) B) Effect of Roscovitine (10 microM) and KRKL region on 
phosphorylation of SLBP fragment were analyzed. GST SLBP fragment with wild type 
KRKL region or 4A mutation were used as indicated below the panel.  
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Figure 7: Phosphorylation detected at late S phase is on Thr61. A) In vitro kinase assays 
with indicated GST-SLBPFragment (ATP, TTP, TAP) or H1 protein were performed in the 
presence of γ32P ATP, using lysates from HeLa cells collected at indicated time points after 
double thymidine block (panel 4,5,6,7). Samples were run on SDS PAGE and 
phosphorylation level of each substrate was determined by autoradiography (panel 4,5,6,7). 
Level of Cyclin A, Cyclin B and SLBP protein in the lysates were examined by western blot 
analysis using corresponding antibodies (panel 1,2,3). B) Whole gel appearance of the kinase 
reactions performed in A-panel 5 detected by autoradiography. 
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Figure 8: Cdk1 is the major Thr 61 kinase in late S phase lysate.  In vitro kinase assay 
using Cdk1, Cdk2 or mock (just beads) immunodepleted late S phase HeLa cell lysates 
(panel 3). Both Cdk 2 (panel 1) and Cdk 1 (panel 2) level in each lysate were deteremined by 
western blot analysis with corresponding antibodies. 
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Figure 9 A) cyclin A/Cdk but not cyclin B/Cdk requires KRKL region for 
phosphorylating Thr 61. Cyclin A or Cyclin B immunoprecipitates from late S phase HeLa 
cell lysate were used in in vitro kinase assays in the presence of γ32P ATP.   Phosphorylation 
on H1 and GSTSLBPfragment (TTP, KRKL/4A, TAP) were detected by autoradiography. 
Phosphorylation level of each substrate were quantified by phosphoimager. Each value is 
normalized against the level of H1 phosphorylation and indicated below corresponding lane. 
B) cyclin/Cdk1 phosphorylates Thr61 much more efficiently than cyclin/Cdk2. Cdk1 or 
Cdk2 immunoprecipitates from late S phase HeLa cell lysate were used in in vitro kinase 
assays in the presence of γ32P ATP.   Phosphorylation on H1 and GSTSLBPfragment (TTP, 
KRKL/4A, TAP) were detected by autoradiography. Phosphorylation level of each substrate 
were quantified by phosphoimager. Each value is normalized against the level of H1 
phosphorylation and indicated below the corresponding lane. In the mock lanes (in A lane 
5,10 and in B lane9) IPs were done with beads alone. 
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Figure 10: Cdk1 knock down inhibits late S phase SLBP degradation. A) Outline of 
experimental setup for RNAi/synchronization procedure. B) HeLa cells were transfected with 
Cdk1 or Control siRNA followed by double thymidine block synchronization. Cells were 
collected at indicated time points after the release from double thymidine block. Levels of 
Cdk1 and SLBP were determined by western blot analysis with corresponding antibodies. C) 
FACs analysis of the 6 hrs time point cells in B with percentage values of each cell cycle 
phase.  
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Figure 11: Thr 61 to Glu change mimic phosphorylation of Thr 61 for degradation 
purposes. A) First threonine in the SFTTP motif has been changed to either aspartic acid or 
glutamic acid and stably expressed in HeLa cells (hisSLBP). Cells were synchronized by 
double thymidine block and collected at indicated hours after release. Levels of exogenous 
mutated histagged SLBP and endogenous SLBP were determined by western blot analysis 
using SLBP antibody. Cells used in lane 10 M were treated with MG132 (proteosome 
inhibitor) 4 hours after release. B) Summary list of the effect of different mutations in TTP 
motif on G2 SLBP degradation. Regulated represents the ones with similar G2 degradation 
profile as endogenous SLBP. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 57
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 58
Figure 12: Model for triggering SLBP degradation at S/G2. Different than cyclin B/Cdk1 
activity which is rapidly boosts at G2/M, gradual increase in cyclin A/Cdk1 activity reaches 
to sufficient level at S/G2 border to trigger SLBP degradation by phosphorylating Thr 61. 
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Figure 13: CkII inhibitors inhibit SLBP degradation at S/G2. HeLa cells were 
synchronized by double thymidine block and CKII inhibitors TBB ( panel 1 lane3, panel 2 
lane 5, 75microM) DMAT (Panel 2 lane2, 10µM, panel 2 lane1, 20 µM), or corresponding 
amounts of DMSO (Carrier) were introduced at 3.5  hours after release for 4.5 hours. Cells 
are collected at indicated time points and western blot analysis was performed with SLBP 
antibody. Panel 1 and Panel 2 are two different experiments done similar way. 
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Figure 14: Thr60 to Glu change did not rescue CKII inhibitor effect. A) HeLa cells 
stably expressing exogenous histagged T60E mutated SLBP were synchronized by double 
thymidine block. 4 hours after release DMSO (Carier, lane 2) or TBB with increasing 
concentrations (20, 40, 60 microM) were introduced for 4 hours. Cells were collected at 
indicated time points and western blot analysis was performed using αSLBP. B) HeLa cells 
stably expressing exogenous histagged E63A mutated SLBP were synchronized by double 
thymidine block and collected at indicated time points after the release. Western blot analysis 
was performed using αSLBP C) Possible effects of CKII in S/G2 SLBP degradation. 
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MATERIAL AND METHODS 
 
            Construct preparation: 
For bacterial expression, the SBLP fragment (51-108) was subcloned into the 
PGEX2T vector just after the GST tag using PCR-generated insert with EcoRI and BamH1 
sites. For expression in HeLa cells, the GST fused SLBP fragment was subcloned into myc-
tagged pcDNA3 vector (Invitrogen) by PCR-generated insert with Xho1 and Kpn1 sites. All 
site-directed mutations were made according to the QuickChange Site Directed Mutagenesis 
protocols (Stratagene) using appropriate complementary oligonucleotides ranging from 30 to 
50 nucleotides in length. All constructs were verified by DNA sequencing. 
 
           Transfection and selection of stable cell lines: 
           HeLa cell plasmid transfections were done with Lipofectamine (GibcoBRL) according 
to the manufacturer's protocol. 2 micrograms of each plasmid was used with each 6 well-
plate. For selection of stably transfected cells, the cells were replated onto a fresh 10-cm 
plate 24 hrs after transfection with media containing 1 mg/ml G418. The medium containing 
G418 was changed every 5 days to remove dead cells. Cells were kept under selection until 
separate colonies could be observed by eye on the plates, and these stably transfected cells (at 
least 20 colonies per plate) were pooled together.  To maintain the stably transfected cells, 
200 µg of G418 per ml was kept in the medium and was removed just prior to 
synchronization. 
           Cell Culture and Synchronization: 
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HeLa cells were grown in Dulbecco modified Eagle medium plus 10% fetal bovine 
serum and penicillin-streptomycin. Cells were synchronized at G1/S border by double-
thymidine block. Cells were plated at a low density 24 h before the start of the 
synchronization protocol when cells were treated with 2mM thymidine for 18 hours for the 
initial block.  After the initial block, cells were washed with PBS and released into fresh 
medium for 9h, and then blocked again with 2 mM thymidine for 16h to arrest all the cells at 
the beginning of S phase. The cells were released into fresh media after washing out the 
thymidine, and lysates were prepared from the cells collected at indicated time points after 
the release. The cells progressed through G2 and mitosis synchronously. The cell cycle 
profile of the cells was determined by propidium iodide staining and flow cytometry analysis 
at UNC Flow Cytometry facility. 
            Lysate preparation and in vitro kinase assays: 
Cells were collected at the indicated time points after release from double thymidine 
block, resuspended in lysis buffer (50 mM β-glycerophosphate, 20 mM NaF, 1.5 mM EGTA, 
0.05% NP-40 with 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 500 µM 
Na3VO4) and sonicated 4 times on ice (800 µl per 10 cm dish).  Extracts were clarified by 
centrifugation for 10 minutes at 14000 rpm at 4oC. In vitro kinase assays were performed in 
30 µl reaction mix (supplemented with final 10 mM MgCl2 and 5 µM ATP) with 
corresponding lysate (1-2 mg/ml protein; 10 µg protein) and 1 µg of substrate (GST-SLBP 
Fragment or H1) in lysis buffer and 8 µCi of [ -32P] ATP. In each reaction, 
immunoprecipitates on beads (from 80-100 µg lysate), the supernatant from the IPs or the 
lysate directly were used as kinase source as indicated. The reactions were incubated at 30oC 
for 30 minutes and stopped by adding 2X SDS loading buffer. Samples were analyzed by 
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SDS-PAGE and each gel wawas Commassie stained, dried and analyzed by autoradiography 
and quantified with a PhosphorImager analysis. 
 
RNAi 
Down regulation of Cdk1 expression was obtained by transfection of chemically 
synthesized siRNA using oligofectamine 2000 transfection according to the manufacturer’s 
protocol. Chemically synthesized siRNAs were obtained from Dharmacon (Lafayette, CO.) 
and had the following sequences of the top strand: 
5′AAGGGGUUCCUAGUACUGCAAdTdT3′ and 5′GGUCCGGCUCCCCCAAAUGdTdT3′ 
(control, C2). A portion of cells were lysed in a buffer containing 150 mM NaCl, 50 mM 
Tris-HCl (pH 8), 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1× protease 
inhibitor mixture (Roche), and 0.5% NP-40 and analyzed by Western blotting. The remaining 
cells were fixed with 70% ethanol and stained with propidium iodide, and were analyzed for 
their DNA content by flow cytometry with a FACscan and the Summit software 
(Cytomation, Inc.). 
Antibodies and inhibitors:   
SLBP was detected with an antibody raised against the C-terminal 13 amino acids of 
the protein (Wang et al., 1996). Cyclin A and Cyclin B antibodies used in western blots and 
immunoprecipitation experiments were purchased from Neomarkers (Feremont, CA) and 
SantaCruz (SantaCruz, CA), respectively. Cdk1 and Cdk2 antibodies were a kind gift from 
Dr. Yue Xiong (UNC). All the kinase inhibitors tested were purchased from Calbiochem (La 
Jolla, CA). 
 
 67
CHAPTER III 
G1 Phase Regulation of SLBP Expression  
 
INTRODUCTION 
 
Stem loop binding protein is the sole factor involved in histone mRNA processing 
that is not present other than S phase (Zheng et al., 2003).  Along with regulation of histone 
mRNA transcription and stability, cell cycle regulation of SLBP is one of the major 
mechanisms that restrict histone mRNA biosynthesis and thus histone production to the S 
phase. SLBP expression is tightly cell cycle regulated. However, SLBP mRNA level does not 
change significantly during cell cycle (Whitfield et al., 2000). As described in Chapter 2, at 
the end of S phase, Cyclin A/Cdk1 triggers rapid degradation of SLBP depending on N-
terminal TTP motif. Cells keep SLBP level low during G1 phase until next S phase when it is 
needed again (Fig 1).  
            Previously, we have introduced translational regulation of SLBP mRNA as one 
mechanism that keeps SLBP level low at G1 using CHO cells. In CHO cells, SLBP 
translation is low at G1 in comparison to S phase although there is not a significant change in 
SLBP mRNA level (Whitfield et al., 2000).  Here, I have further confirmed this regulation in 
HeLa cells by comparing the amount of newly expressed SLBP by 35S-methionine labeling 
of both G1 and S phase cells and determining the SLBP mRNA distribution on polysomes in 
G1 and S phase HeLa cells by sucrose gradient fractionation. Further, I have shown that 
coding sequence of SLBP mRNA is sufficient to introduce low translational rate at G1 in 
comparision to S phase. 
As a new insight into SLBP G1 regulation, I have shown that somewhere between 
early and mid G1, SLBP translational efficiency recovers back to S phase level and I have 
introduced increased instability of the SLBP protein as a new mechanism that keeps SLBP 
expression limited during rest of G1. Our findings here suggest regulated degradation as a 
possible new mechanism that keeps SLBP level controlled during G1.  
 
RESULTS 
 
SLBP mRNA translation rate is low at early G1. 
After degradation of SLBP at S/G2, the SLBP level remains low with only limited 
gradual increase until prior to the next S phase (Fig 1 and Fig 6A). As cells approach S 
phase, SLBP level increases significantly, reaching the level present in cells arrested at the 
G1/S border by double thymidine block (Fig 1), without a significant change in SLBP 
mRNA level (Whitfield et al., 2000). The G1 stage of the cell cycle is often the longest 
period of mammalian somatic cell cycle, and varies greatly between different cell types and 
in different growth conditions. In rapidly cycling HeLa cells, it lasts up to 6-8 hours. The 
SLBP level recovers back to S phase level at late G1 or G1/S border which is about 16-18 
hours after release.  A problem with studying G1 is that this is also the phase of the cell cycle 
that varies most within cells in a culture.  Cells progress relatively stochastically through G1, 
resulting in a distribution of times that cells enter S-phase, while cells released from the 
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double thymidine block progress very synchronously through S-phase, G2 and mitosis. In 
this study, I have defined early G1 as between 11-12.5 hours after release from double 
thymidine block and after that point to late G1, I have considered as mid-G1. 
In parallel with previous findings from the Marzluff lab using CHO cells, I have 
confirmed that also in HeLa cells SLBP translation rate is low at early G1. To compare 
production rate of new SLBP protein between early G1 and S phases, I labeled newly 
produced proteins, in vivo by treating cells with media containing 35S labeled methionine for 
15 minutes after 30 minutes of incubation in media lacking methionine. For these 
experiments, I synchronized cells at G1/S with double thymidine block and for early G1 
cells, I released them for 11.5 hrs where cells have divided and have entered the next G1-
phase. For S-phase cells, I have used cells at 2 hours after release from double thymidine 
block.  
After labeling, first, I analyzed an equal amount of total protein of labeled extracts by 
running on SDS PAGE, I have shown that the general level and pattern of newly produced 
proteins was comparable demonstrating that the synthesis of the most abundant cellular 
proteins is very similar in G1 and S phases (Fig 2A). From these lysates, I specifically 
immunoprecipitated SLBP.  The amount of newly produced SLBP in early G1 was 3-4 fold 
lower than the amount of newly synthesized SLBP precipitated from the S-phase lysates (Fig. 
2A).  
One reason for keeping protein levels low is to rapidly degrade newly synthesized 
proteins. This mechanism is used to regulate the level of Cyclin A during G1 in continuously 
cycling cells (Brandeis and Hunt, 1996).  To check whether there is rapid degradation of 
SLBP at this point of cell cycle, I treated those early G1 cells with the proteosome inhibitor 
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MG132 for one hour.  The level of SLBP protein remained low, indicating rapid degradation 
of newly synthesized protein is not the case for SLBP. On the other hand, the levels of Cyclin 
A protein, which is continuously degraded during G1 starting from the late mitosis, increased 
in response to treatment with proteosome inhibitor in the same early G1 cells (Fig 2B).  
A second approach to determine the stability of a protein is to treat cells with an 
inhibitor of translation, cycloheximide and measure the levels of the protein.  Using this 
approach, I have further shown that there is no rapid degradation of SLBP in early G1. When 
I blocked new protein synthesis by treating cells with translation inhibitor Cycloheximide for 
one hour at early G1 the SLBP level did not change, although the low Cyclin A levels did 
decrease (Fig 2C).  Thus two independent approaches confirm that rapid degradation of 
newly synthesized protein is not the reason for the low level of SLBP we detected with early 
G1 cells (Fig 2B, C), and is consistent with a lower SLBP translation efficiency in early G1 
compared to S-phase cells. 
To further confirm the possible translational regulation, I compared the polysome 
distribution of SLBP mRNA at early G1 and S phase cells. I have performed sucrose gradient 
fractionation with the cytoplasmic lysate from early G1 and S phase cells. Total RNA from 
each fraction was isolated and run on agarose gel and ETBR stained. Based on the 
appearance of 18 S and 28 S ribosomal RNAs, I have detected monosomes around fraction 3, 
4 where I have detected both ribosomal RNAs together first time and as fractions get with 
higher density presumably contains growing chain of polysomes. In order to detect 
distribution of SLBP mRNA on the polysomes, I synthesized cDNA with oligo dT primed 
reverse transcription, followed by PCR with specific primers against SLBP mRNA. In the 
cytoplasmic extract from the early G1 cells, I have determined peak level of SLBP mRNA 
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around fractions 12 and 13 corresponding with smaller polysomes (Fig 3A). In the case of S 
phase extracts SLBP mRNA peak shifted to the fractions with highest density corresponding 
to largest polyribosomes  (Fig 3B). As control when I compared the mRNA distribution of a 
housekeeping gene, GAPDH, which is expressed constitutively I did not detect a significant 
difference in profile of GAPDH mRNA distribution on polyribosomes (Fig 3).  Thus, we 
concluded that SLBP mRNA translation rate is low in early G1 phase in comparison to S 
phase. 
 
The SLBP coding sequence is sufficient to introduce G1 translational regulation.  
I then tried to determine possible sequence element(s) in SLBP mRNA that are 
responsible for introducing this cell-cycle dependent translational regulation. First, I asked 
the question whether SLBP coding sequence is sufficient to introduce the difference in SLBP 
translational efficiency in G1 and S phase.  I cloned the SLBP coding sequence into pcDNA3 
vector resulting in a his-tagged protein, which can be distinguished from endogenous SLBP 
and stably expressed this construct in Hela cells (Fig 4A). Next, I synchronized those cells 
with double thymidine block and determine the expression of the endogenous and exogenous 
SLBP protein in G1. I detected similar low expression level of exogenous his-tagged SLBP 
during G1 as I detected with the endogenous SLBP (Fig 4B).  
Next, using immunoprecipitation of SLBP from 35S methionine labeled cells, I have 
shown that newly produced exogenous SLBP is low in early G1 in comparison to S phase 
cells just like endogenous SLBP (Fig. 5A). Note that, when analyzing the total extracts, there 
is no significant difference in labeling of the abundant cellular proteins between G1 and S 
phases, suggesting that this regulation is specific for SLBP (Fig. 5A). I have further shown 
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that like endogenous SLBP, exogenous SLBP level does not change in response to 
cycloheximide or MG132 (Fig 5B, C), showing that like endogenous SLBP, exogenous his-
tagged SLBP is not rapidly degraded at that time point.  Based on these findings, I conclude 
that the SLBP coding sequence is sufficient to introduce cell cycle dependent specific 
translational regulation of SLBP.  
 
Regulated degradation in mid-G1 as a new mechanism to regulate SLBP 
expression later in G1. 
Next, in order to check whether the low level of SLBP translation efficiency is the 
case for the entire G1 or only limited to very early G1, I compared the rate of newly 
produced SLBP in later points in G1 (mid G1, 13 hrs after release) with the rate in S phase 
cells (2 hrs after release) by performing 35S methionine labeling followed by SLBP 
immunoprecipitation experiments with corresponding cell cycle stage lysates. I have shown 
that in contrast to early G1, the level of newly produced SLBP later in G1 is similar to S 
phase level suggesting that translation efficiency recovers to the S phase level somewhere in 
between early and mid G1 (Fig 6).  
Although it seems that the level of SLBP translation increases to S phase level around 
mid G1, the amount of SLBP protein expression remains relatively low for another 3 hours 
until late G1 or G1/S before recovering back to S phase level suggesting that there may be 
additional mechanisms that can keep SLBP expression limited in this period of G1 until next 
S phase.  
A possible mechanism to limit SLBP expression could be regulated degradation. This 
is the case in G1 for several other S phase related proteins like Cyclin A, Skp2, Cdc6 
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(Petersen et al., 2000; Bashir et al., 2004; Wei et al., 2004a). To check this possibility, I have 
repeated cycloheximide experiments to determine the stability of SLBP this time around 1 
hour later in G1. In contrast to SLBP in early G1 cells, SLBP level decreased as did the  
positive control Cyclin A which is already known to be unstable in G1 (Fig 7A). Moreover, 
like endogenous SLBP, stably expressed exogenous SLBP was also unstable in mid-G1 cells 
although the small amount present in earlier point of G1 was stable (Fig. 5). In Figure 7B, I 
have observed rapid degradation of SLBP at S/G2 as expected. 
These findings suggest possible change in the rate of degradation of SLBP as a 
second mechanism to control the level of SLBP expression during G1 prior to the point that 
SLBP level reaches to S phase level somewhere at late G1.  This increased degradation of 
SLBP occurs somewhere between early and mid-G1 cells, but not in early G1 cells. 
  
DISCUSSION 
 
As a key player in histone mRNA metabolism, SLBP expression is tightly regulated 
during the cell cycle.  Previously, I have shown that Cyclin A/Cdk1 triggers rapid 
degradation of SLBP at S/G2 border. Here, I have shown that during G1, SLBP level kept 
low until the next S phase via at least two mechanisms. First, I have confirmed that low 
translation efficiency as one of  the mechanisms to keep SLBP level low at early G1 and 
have shown that SLBP coding sequence is sufficient to mediate this regulation. Further, I 
have shown that the low translation efficiency recovers to the S phase level somewhere 
between early and mid-G1 phase and I have proposed regulated degradation as an additional 
mechanism that may be keeping SLBP levels low until S phase.  
 74
 Low translation rate of SLBP in G1 is mediated by its coding sequence. 
During G1, SLBP expression is limited until G1/S border (or late G1). After SLBP is 
degraded rapidly at S/G2 and cells complete M phase, it takes around 8 hrs for HeLa cells to 
progress to the point at G1/S border where SLBP expression level come back to S phase 
level.   
Previously, Mike Whitfield in the Marzluff lab, showed a low production rate of 
SLBP in G1 cells in comparison to S phase cells in CHO cells. Further, he had shown that 
SLBP mRNA level is not regulated during the cell cycle in either CHO or HeLa cells. Here, I 
have confirmed that translation rate of SLBP mRNA is lower at early G1 point in comparison 
to S phase rate also in HeLa cells, by comparing new SLBP synthesis rate and SLBP mRNA 
polysome distribution in G1 and S phase HeLa cells and showing that SLBP is not rapidly 
degraded at this point of cell cycle (Fig 2).   
Although we have determined that SLBP translation rate is low in early G1, the 
nature of this regulation is still unknown. It is still not clear whether SLBP translation is kept 
low by active inhibition in early G1 by a binding of specific protein or miRNA, which is 
simply removed as cells approach S-phase, or whether there is active triggering by activation 
or expression of certain factors that facilitates SLBP translation.  It is also possible that SLBP 
mRNA translation is activated as a result of an increase in a limiting general translation 
factor. 
In order to elucidate the mechanism, I have tried to find a cis-element(s) in SLBP 
mRNA that is responsible for the translational regulation. For this purpose, I have first 
checked whether SLBP coding sequence is sufficient to introduce low translation efficiency 
 75
in early G1 cells as endogenous SLBP. In HeLa cells, I have stably expressed vector where I 
have cloned in only SLBP coding sequence but not the UTRs. When I repeated rapid 
degradation and 35S experiments with those HeLa cells, the his-tagged exogenous SLBP 
showed similar profile as endogenous SLBP.   
Based on these findings I concluded that SLBP coding sequence is sufficient to 
introduce the difference between SLBP mRNA translation efficiency in early G1 and S phase 
cells. Further mapping of possible cis-element in coding sequence and determination of 
whether there is any contribution from UTRs is yet to be done.   
Since in somatic cells there is only a couple of examples of coding sequence 
dependent translation regulation (Stajduhar et al., 2000; Lin et al., 2000; Tai et al., 2004a), 
and all miRNAs published so far are targeting 3’UTR, this may be interesting and novel 
regulation. miRNAs that are targeting coding sequences have been recently discovered and 
are yet to be published (personal communication with R. Agami).  
 
Regulated degradation is a possible second mechanism to limit SLBP expression 
level in G1. 
In this chapter, I have introduced a second possible mechanism to limit the level of 
SLBP expression in G1 phase. I have shown that new SLBP production rate increases to the 
S phase rate somewhere between early and mid-G1 (Fig 6), although it takes another 3 hours 
for SLBP expression to reach the S phase level (Fig 1). This observation suggested the 
presence of another mechanism to control SLBP levels until G1/S border. Since the SLBP 
production rate is the same in mid-G1 as in S-phase, the other possibility to restrict SLBP 
expression may be the instability of the protein. When I checked the stability of SLBP by 
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blocking new protein production with cycloheximide, I found that, unlike the earlier point in 
G1, the SLBP level goes down around 50 % in one hour (Fig. 7), suggesting involvement of 
regulated degradation as a second mechanism to coordinate SLBP expression and S phase 
entry.  
 Thus according to my current model (Fig. 8), at least two mechanisms are involved in 
keeping SLBP levels low in G1-phase (Fig. 8). At early G1, SLBP translation is low in 
comparison to S phase, but the small amounts of SLBP protein are stable. At sometime later  
in G1, the SLBP production rate increases to the S phase rate but regulated degradation keeps 
SLBP level limited until next S phase. This allows significant increase in SLBP levels just 
before S phase when this degradation stops.  
 
            Possible mechanism for regulation of SLBP degradation in G1. 
 A possible candidate for the factor that targets SLBP for degradation in mid-G1 is the 
APC. There are at least two forms of the APC: APCCdh1 and APCCdc20.  The initial active 
form is APCCdc20 which is responsible for degradation of Cyclin A and B at the end of 
mitosis.  APCCdh1 becomes active after M phase Cyclins degradation at late M phase and 
remains active during G1 until it gets inactivated as cells approach S-phase.    Cdk activity 
promotes APCCdc20 activity and prevents APCCdh1 activity.  The kinetics of switch from 
APCCdc20 activity to APCCdh1 activity at M/G1 is not very well determined. It is also 
possible that there are additional activating factors that have not been described for the APC. 
            It is possible due to the fact that Cyclin A is strong target  for both forms of APC, at 
immediately after M/G1, we can detect Cyclin A degradation, on the other hand SLBP 
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degradation can be detected after somewhere in early G1 where APCCdh1 activity and 
possibly the SLBP level reaches to certain level.   
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Figure 1) SLBP level stays low until the next S phase in HeLa cells. A) Western blot 
analysis of SLBP expression in HeLa cells collected at indicated time points after release 
from double thymidine block. B) FACs analysis of the cells collected at indicated times after 
the release.  
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Figure 2: SLBP translation efficiency is low in early G1 cells. A) HeLa cells are labeled 
with 35S-methionine for 15 minutes at early G1 or S phase (12 and 2.5 hrs after double 
thymidine release, respectively) after half hour incubation in methionine lacking media. 
Equal protein amounts of total lysates  (Panel 1 ) and immunoprecipitates with SLBP 
antibody or beads alone (panel 2) were run on SDS PAGE gel and detected with 
autoradiography. B) Western blot analysis of the cells collected after one hour MG132, 
DMSO (carrier) or just media treatment at early G1 (between 11.30 and 12.30 hrs after 
release from double thymidine block) using Cyclin A or SLBP antibody as indicated. 
 C) Western blot analysis of early G1 (11.30 hrs after release) cells before and after 1hour 0.1 
M Cycloheximide treatment, using Cyclin A or SLBP antibodies as indicated.  
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Figure 3: SLBP mRNA shifts from small to large polysomes between early G1 and S 
phase. Hela cells were synchronized by double thymidine block and collected at either 2 
hours after release (B) or 11.30 hours after release (A). Cytoplasmic lysates were prepared 
and fractionated on 15 to 40 % sucrose gradient, and RNA was prepared from each fraction. 
The RNA was resolved by agarose gel electrophoresis and stained with EtBr (top panels). 
Using RNA from each fragment, RT PCR targeting either SLBP or GAPDH mRNA were 
performed. 
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Figure 4: SLBP coding sequence clone (his-SLBP) expression is low at G1. A) SLBP 
coding sequence is cloned in to pcDNA3 vector and stably expressed in HeLa cells. B) 
Western blot analysis of HeLa cells stably expressing exogenous histagged-SLBP collected 
at indicated times after double thymidine block with SLBP antibody. 
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Figure 5: SLBP coding sequence is sufficient to introduce low translation efficiency in 
early G1 cells. A) HeLa cells expressing exogenous histagged SLBP are labeled with 35S-
methionine for 15 minutes at early G1 or S phase (12 and 2 hrs after double thymidine 
release, respectively) after incubating half hour in media without methionine. Equal protein 
amounts of total lysates (Panel 1) and immunoprecipitates with SLBP antibody or beads 
alone (panel 2) were run on SDS PAGE gel and detected with autoradiography. B) Western 
blot analysis of early G1 (11.30 hrs after release) cells before and after 1 hour 0.1M 
Cycloheximide treatment using Cyclin A or SLBP antibodies.  C) Western blot analysis of 
the cells collected after one hour MG132, DMSO (carrier) or just media treatment between 
11.30 and 12.30 hrs after release from double thymidine block using Cyclin A or SLBP 
antibody as indicated. 
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Figure 6: SLBP translation efficiency recovers to S phase level between early and mid-
G1. HeLa cells are labeled with 35S-methionine for 15 minutes at early G1 or S phase (13 and 
2 hrs after double thymidine release, respectively) after incubation in methionine lacking 
media for half hour. Equal protein amounts of total lysates (Panel 1) and immunoprecipitates 
with SLBP antibody or beads alone (panel 2) were run on SDS PAGE gel and detected with 
autoradiography.  
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Figure 7: SLBP is less stable at mid-G1. A) HeLa cells expressing exogenous 
histaggedSLBP were treated with 0.1M Cycloheximide for 1 hour at mid-G1 (13 after double 
thymidine release). Western blot analysis of the cells before and after treatment were 
performed by using Cyclin A or SLBP antibody. B) HeLa cells were treated with 0.1 M 
Cycloheximide for 1 hour at S phase and S/G2 (2.30 hrs and 6 hrs after double thymidine 
release). Western blot analysis of the cells before and after treatment were performed by 
using SLBP antibody. 
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Figure 8: Model for regulation of SLBP expression in G1. In early G1 SLBP translation 
rate is low. Between early and mid G1 SLBP translation efficiency increase to S phase level 
but yet SLBP protein level kept limited by regulated degradation until next S phase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 93
 Early G1 Late G1Mid G1
Low SLBP 
Translation
SLBP Translation  
Regulated Degradation 
S phase
SLBP level
 
 
  
 94
MATERIALS AND METHODS: 
 
. 
Determination of SLBP synthesis rate: 
HeLa cells were synchronized by double tymidine block as explained in Chapter 2. 
Early G1 cells (11.15 hrs after release) and S phase cells ( 2 hours after release) were 
preincubated in DMEM, without methionine supplemented with 10% dialyzed fetal bovine 
serum,  for 45 mins  prior to labeling to deplete intracellular stores of methionine. SLBP 
synthesis rate was measured by pulsing cells with 1 mCi of [35S]methionine for 15 min. 
Whole-cell extracts were incubated with anti-SLBP and the SLBP–antibody complexes 
recovered by binding to protein A agarose beads. The bound proteins were eluted in SDS 
loading buffer and resolved by gel electrophoresis and detected by autoradiography. 
 
Polysome fractionation:  
HeLa cells were synchronized as explained as Chapter 2. HeLa cells at early G1 
(11.30 hours after release) and S phase (2hrs after release) were lysed in hypotonic buffer and 
the nuclei and mitochondria removed by centrifugation. The cytoplasm was adjusted to 0.1% 
NP-40, 0.1 M NaCl, 5 mM Mg(OAc)2 and layered on a 15–40% sucrose gradient containing 
0.1 M NaCl, 5 mM Mg(OAc)2, 10 mM Tris, pH 7.5.  Polyribosomes were fractionated by 
centrifugation at 39 000 r.p.m. for 2.5 h in an SW841 rotor.  Aliquots of 0.5 ml were 
collected and RNA was prepared from 0.3 ml of each aliquot using Trizol LS according to 
manufacturer’s direction. RNA prepared from each fraction was analyzed by agarose gel 
electrophoresis to identify the monoribosome peak. In order to detect SLBP and GAPDH 
mRNA I have designed primers that are targeting 200 nucleotide region in their coding 
 95
sequences with comparable GC content. After RNA isolation from each fraction, RNA was 
subject to reverse transcription (RT) using the manufacturer's protocols (New England 
Biolabs, Natick, MA) with random hexamer primers. Approximately 1/10 of the RT reaction 
was used as a template for 20 cycles PCR to detect GAPDH and SLBP mRNAs. 
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CHAPTER 4 
CONCLUDING DISCUSSION 
 
SLBP expression is limited to S phase where it functions. SLBP expression as major 
player in histone biosynthesis is tightly regulated during cell cycle. I have determined that 
cells restrict SLBP expression to S phase via several different mechanisms. At S/G2, SLBP is 
rapidly degraded depending on specific phosphorylations at Thr 60 and Thr 61, with the 
phosphorylation on Thr 61 by cyclinA/cdk1 as the likely event that triggers SLBP 
degradation. At M to early G1, SLBP translation is low due to mechanism mediated by its 
coding sequence. And finally, as a possible new mechanism to regulate SLBP expression in 
G1, SLBP expression is controlled by regulated degradation until next S phase. 
 
SLBP Expression and the S/G2 Transition. 
 
Here, I have determined that SLBP degradation at S/G2 is triggered by Cyclin 
A/Cdk1 mediate Thr 61 phosphorylation. Cyclin A/Cdk1, different than Cyclin B/Cdk1 
which shows rapid activation at G2/M, shows gradual activity increase starting in late S 
phase increasing towards G2 phase where it peaks (Pagano et al., 1992; Mitra et al., 2006).  
According to our model, at S/G2, Cyclin A/Cdk1 activity reaches sufficient level and triggers 
SLBP degradation by phosphorylating Thr 61. 
The S/G2 transition is one of the least understood stages of cell cycle. Here, we 
introduce Cyclin A/Cdk1 as player in this stage where it triggers degradation of SLBP as a 
mechanism to end histone biosynthesis which is one of the major events that is performed in 
S phase. It is an appealing idea that Cyclin A/Cdk1 plays several other roles including 
triggering degradation of several other proteins at S-G2 transition. One of the candidates for 
this kind of regulation is degradation of E2F1 which is also degraded at almost same cell 
cycle point as SLBP. Dr. Jian Dong in the Marzluff lab has shown that S/G2 degradation of 
E2F1 is mediated by phosphorylation of a central region of E2F1 which is different than 
previously determined Skp2 targeting site. Further, this degradation requires a RXL motif 
and is sensitive to roscovitine just like SLBP. We are currently investigating whether Cyclin 
A/Cdk1 is the kinase that triggers E2F1 degradation at S/G2 similar to SLBP. 
Finally, the fact that SLBP can distinguish between Cyclin A/Cdk2 and Cyclin 
A/Cdk1 as kinase for the phosphorylation of Thr 61 can provide explanation for cell cycle 
events that are believed to be mediated by Cyclin A/Cdks but yet don’t happen during S 
phase where there is high Cyclin A/Cdk2 activity, but instead occur in G2 phase.    For 
example, Cyclin A/Cdk is believed to have role in Cyclin B/Cdk1 activation. On the other 
hand although there is high Cyclin A/Cdk2 activity throughout S phase this event occurs at 
G2.  It is possible that Cyclin A/Cdk1 activity may be needed a possible initial, activating 
phosphorylation of Cdc25C and/or inhibiting phosphorylation of Wee1 to trigger Cyclin 
B/Cdk1 activation loop for robust Cyclin B/Cdk1 activation and M phase entry. It is likely 
that there will be other specific substrates of Cyclin A/Cdk1.  Already a few examples have 
been identified (Henneke et al., 2003; Li et al., 2004; Baldin et al., 1997). 
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In conclusion, I believe that the role I propose here for Cyclin A/Cdk1 at the time of S 
phase completion may be an example of several other biochemical events that Cyclin 
A/Cdk1 is regulating at S/G2 transition.   
A remaining unknown question is what ubiquitin ligase is necessary for SLBP 
degradation at the end of S-phase.  Dr. Dong and I knocked down a number of the cullin 
proteins, but none of these had convincing effects on SLBP levels in exponentially growing 
cultures.  Since knocking down a cullin generally affects the cell cycle enough that we could 
not subsequently synchronize the cells, it was not possible to definitively ask if any of these 
ligases had a specific effect at G2.  Since the form of SLBP that is recognized for degradation 
is the doubly phosphorylated form, and it has not been possible to create phosphomimics that 
are degraded appropriately, it has not been possible to develop biochemical approaches to 
find binding partners for the SLBP to allow its degradation.  The recent finding that the E 
change at Thr 60 mimics phosphorylation at this site, together with the ability to 
phosphorylate Thr 61 in vitro, makes potential biochemical approaches possible to identify 
the ligase.    
 
G1 phase regulation of Stem loop binding protein. 
 
Low translation rate at early G1. 
I have further confirmed that SLBP translation is low at early G1 in comparison to S 
phase in HeLa cells. In contrast to our previous model, I have shown that SLBP translation 
rate comes back to S phase level not at G1/S (16/18hrs after release) somewhere between 
early and mid G1. Further, I have shown that coding sequence of SLBP is sufficient to 
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introduce this low translation rate. The nature of this regulation is yet to be determined.  It is 
critical to determine whether there the sequences in either the 5’ or 3’ UTR that are also 
involved in the translational regulation.  In addition it should be possible to narrow down the 
regions required for translation regulation by deletion analysis, creating proteins that react 
with our antibody but lack a tag which may affect the half-life of the protein.  Translational 
regulatory regions in the coding region are unusual, and it is not clear how they might 
function to reduce translation efficiency,    
During M phase, general translation (Cap dependent translation) is inhibited majorly 
due to scarce level of active eiF4F complex.  From M phase to G1, translation machinery 
recovers back to active state and at G1 there is robust translation. In G1, mTOR and MAPK 
pathways further activate the translation machinery and are important for G1 progression as 
explained in Chapter 1. This kind of global regulation on translation machinery can introduce 
relatively specific effect on certain mRNAs due to properties like their high 5’ GC rich 
content which introduces secondary structures. It is possible that at M/G1 transition although 
translation of the most of the mRNAs recovers, some of the mRNAs require further 
activation of translation machinery by for example mTOR and/or MAPK pathways in G1. It 
is possible that the low translation rate that we detect with SLBP in early G1 is an example of 
a selective effect of changes in global translation regulation due to some intrinsic property of 
SLBP coding sequence that makes it more vulnerable to the any change in the general 
translation machinery.  
Possible signal that causes transition from low to high SLBP translation remains to be 
an interesting question. It is possible to block candidate signals known to take role in G1 like 
mTOR, MAPK and Cdks. On the other hand, since blocking these signals introduces cell 
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cycle block or delay it is difficult to asses whether the possible effect seen on SLBP is direct 
or indirect.  Another possibility about the nature of SLBP translation regulation can be 
specific regulation by a protein or miRNA that recognizes certain cis-element within the 
coding sequence. Since there is limited number of examples of coding sequence dependent 
translation regulation(Stajduhar et al., 2000; Lin et al., 2000; Tai et al., 2004b) , and all 
miRNAs published so far are targeting 3’UTR , this may be interesting and novel regulation. 
As recent developments, miRNAs that are targeting coding sequences have been discovered 
and are yet to be published (personal communication with R. Agami).  
 As a future direction, being able to determine a possible cis-element responsible for 
this regulation will be important to understand the nature of this regulation. If we can 
determine a cis-element that is required and sufficient to introduce this regulation, this 
sequence can be used as bait to identify any protein that can specifically bind to it. Also, in 
order to check possible involvement of a miRNA, to be able to block any possible miRNA 
targeting this cis-element, 2OH methyl modified version of this sequence can be transfected 
to see if it can block translational regulation of SLBP. 
 
Regulated degradation of SLBP at G1.  
Here, I have introduced regulated degradation as an additional mechanism to control 
SLBP expression in G1. I have shown that low translation efficiency of SLBP recovers back 
to S phase level during G1 but yet SLBP expression does not recover back to S phase level 
until G1/S which is around 3-4 hours later. SLBP stability is low during this period which 
may be the cause low SLBP expression during G1.  
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APCCdh1 is known to be regulating the expression of several S phase related proteins 
like Cyclin A, Skp2 and Cdc6 in G1(Petersen et al., 2000; Bashir et al., 2004; Wei et al., 
2004b). It becomes active after degradation of M phase Cyclins at late M phase until next S 
phase where Cyclin A/Cdk2 activity and expression of APC inhibitor Emi-1 block its 
activity(Herman-Antosiewicz et al., 2007; Fung and Poon, 2005).  One of the known target 
motif for APC is so called Destruction box (D-box) with some version of RXXL sequence. 
SLBP has two highly conserved RXXL motif at its N-terminal which fits with the appealing 
possibility that APCCdh1 regulates expression of another S phase protein-SLBP in G1.  It is 
possible that SLBP translation rate is low at M/G1 and towards mid-G1 it comes to S phase 
level while APCCdh1 activity (and may be SLBP level, too) reaches to the level to be able to 
target SLBP as a new mechanism to limit the SLBP expression by targeted degradation until 
next S phase.  In order to determine the possible region(s) of SLBP that targets it to regulated 
degradation, I have produced several deletions of SLBP (including RXXL regions) and I am 
in the process of stably expressing them in HeLa cells. In order to differentiate G1 
degradation from S/G2 degradation, I have also mutated Thr 61 to prevent S/G2 degradation. 
Next, using those cells, I will try to map the possible region that is needed for G1 regulated 
degradation of SLBP.  
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